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 I 
Abstract 
Based on previous studies of the novel Lactobacillus reuteri DPC16 strain, an in vitro 
investigation on the supernatant antimicrobial activity and the culture safety against 
normal gastrointestinal microflora and gastric mucus was done in this thesis.  
DPC16 cell-free supernatants (fresh and freeze-dried, designated as MRSc and 
FZMRSc) from anaerobic incubations in pre-reduced MRS broth, have shown 
significant inhibitory effects against selected pathogens, including Salmonella 
Typhimurium, E. coli O157:H7, Staphylococcus aureus, and Listeria monocytogenes. 
These effects were mainly due to the acid production during incubation as evidenced by 
the negation of such activity from their pH-neutral counterparts, and this acidic effect 
was shown to reduce the pathogen growth rate and decrease the total number of 
pathogen cells.  
By incubation of concentrated (11 g/L) resting cells in glycerol-supplemented MRS 
broth, another DPC16 cell-free supernatant (designated as MRSg) has shown very 
strong antimicrobial effect against all target pathogens. As indicated by a kinetic profile, 
this activity developed in a sigmoidal fashion as incubation proceeded, reaching to 
maximum activity after 6-8h and maintained at the same level thereafter. Further study 
has shown that the antimicrobial activity of this supernatant was pH-independent, 
effective across a pH range of 4.6 to 6.5, and acted on both Gram-negative and 
Gram-positive pathogens. Using the minimum effective dose, a time course 
investigation has provided evidence that this supernatant affected the growth of the 
target pathogens by elongating the lag phase and lowering the total cell number at the 
end of the incubation. Lastly, it was found that the strong antimicrobial effect of MRSg 
was bactericidal at high concentrations and bacteriostatic at low concentrations. 
However, it also found that the viability of DPC16 cells also decreased as incubation 
prolonged, which suggests that this glycerol-derived supernatant had a lethal effect to its 
own cells. Nevertheless, this lethal effect was exerted to a much lesser extent compared 
with that to the pathogens.  
The last DPC16 cell-free supernatant was designated as SGF, which was produced from 
secondary fermentation of the same resting cells in glycerol-water. SGF did not show a 
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significant antimicrobial activity, which suggests that this specific strain is not capable 
of utilising glycerol in the absence of fermentable carbohydrates.  
The antimicrobial activity found in MRSg matched with previously published 
characteristics of reuterin, which is a unique antimicrobial substance synthesised by L. 
reuteri when incubated with glycerol. Therefore, a study on the production kinetics of 
reuterin by DPC16 was carried out. Supernatants of both MRSg and SGF were studied. 
Results showed that glycerol utilisation occurred in both MRSg and SGF, whereas the 
bioconversion of glycerol into reuterin was different. In MRSg, glycerol was constantly 
utilised by DPC16 resting cells, and by the end of an 18h incubation 85.8 mM of 
glycerol was utilised, where 72.8% was transformed into reuterin. The formation of 
reuterin initiated with an inclining production and reached the maximum rate of 10.9 
mM/h after 6h of incubation, with the total production of 64 mM of reuterin at the end 
of the 18h incubation. This reuterin production in MRSg followed a similar pattern to 
that of its antimicrobial activity, which suggests a certain correlation between reuterin 
formation and the increase of antimicrobial activity in MRSg. Therefore, the major 
antimicrobial component in MRSg that accounted for its potent antimicrobial activity 
was very much likely to be reuterin. In SGF, however, detectable reuterin was negligible 
even though some glycerol may have been absorbed into the highly concentrated 
DPC16 resting cells. This has responded to the antimicrobial activity assay in that due 
to the lack of essential carbohydrate nutrient for normal cell metabolism, there was no 
glycerol utilisation and hence no reuterin synthesis.  
Having studied the antimicrobial activity of L. reuteri DPC16 and the production of 
antimicrobial-competent reuterin, two safety issues (the impact on growth on other 
normal commensal probiotics and mucin degradation activity) of this strain were 
assessed to further evaluate its probiotic potential. By using similar in vitro assays as in 
the antimicrobial test, the same set of DPC16 supernatants have demonstrated no 
adverse effect on the growth of either Lactobacillus acidophilus, Lactobacillus 
plantarum, Pediococcus acidilactici, or Bifidobacterium lactis DR10. No stimulatory 
effect was found either. By incorporating purified porcine gastric mucin into classic 
mucin-degradation assays in both liquid and agar media, DPC16 has not exhibited the 
same mucinolytic activity as that of the faecal flora cultures. Thus, it can be concluded 
that L. reuteri DPC16 is as safe to the host as normal commensal microflora.  
Acknowledgement                                    
 III 
Acknowledgement 
First of all, I wish to take this opportunity to express my most sincere gratitude to all my 
supervisors who have helped and supported me with the completion of this thesis. 
Without their advice and encouragement, this thesis would not have been possible.  
In particular, I would like to thank my chief supervisor, Dr. Abdul Molan, for his 
professional guidance and continuous encouragement throughout the course of this 
thesis.  
Equally, I am sincerely grateful to my co-supervisor, Professor Ian Maddox, for his 
long-term supervision, concerns and encouragements since 2005.  
I will also thank Dr. Quan Shu, my third supervisor, for his leadership and for offering 
me this opportunity to study and research.   
I wish to express my sincere gratitude to Bioactive Research New Zealand Ltd., who 
not only funded this research, but also provided all the stock bacteria strains and 
extensive laboratory supports.  
I will also acknowledge my gratitude to Crop and Food Research at Mt. Albert Research 
Centre, Auckland, for their generous and kind support with lab facility. Specifically, I 
would thank Graham Fletcher, Graeme Summers, Douglas Rosendale, Muftikhar 
Ahmed, and the former laboratory manager Mr. Joseph Yoseph. Without their helps and 
kind supports, this thesis would not have been completed to the current extent. In 
addition, I would acknowledge my special thanks to Douglas Rosendale for not only 
advising me on my experiments but also proofreading the thesis. 
I am also grateful to the colleagues and research fellows working at Bioactive Research, 
including the technical and production manager, Robert Peng, the PhD candidate 
Sabrina Tian and Sean Chen. The discussion forum we established has equipped me 
with knowledge and ideas in scientific discovery.  
Finally, I would like to thank my family, my wife Sunny R. Han, my son David Bian, 
and my parents in China. Their endless love, support and encouragement were the fuel 
driving me towards the accomplishment of this research.  
Abbreviations                                   
 IV 
Abbreviations 
3-HPA 3-hydroxypropionaldehyde 
BbL B. lactis DR10 culture 
BHI Brain heart infusion broth  
EMP Embden-Meyerhof pathway 
FF Faecal flora culture 
FHEF Facultative hetero-fermentation 
FZMRSc Aqueous solution of freeze-dried MRSc 
GI Gastrointestinal 
HFF Heat-killed faecal flora culture  
LAB Lactic acid bacteria 
LR L. reuteri DPC16 culture in pre-reduced MRS 
LRg L. reuteri DPC16 glycerol fermentation 
MAP Modified atmosphere packaging 
MIC Minimum inhibition concentration 
MRSc   DPC16 supernatant from incubation in MRS 
MRSg DPC16 supernatant derived from glycerol-MRS incubation 
NAD+      Nicotinamide adenine dinucleotide  
NADH   Reduced form of NAD+ 
OD  Optical density 
OHEF   Obligate hetero-fermentation 
OHOF   Obligate homo-fermentation 
PBS         Phosphate buffered saline 
PKP     Phosphoketolase pathway 
PGM         Porcine gastric mucin     
RPM Revolution per minute 
SCFA Short chain fatty acids 
SEM Standard error of the mean 
SGF Sole glycerol ferment  
(DPC16 supernatant from glycerol-water fermentation) 
 
Table of Content 
 V 
Table of Content 
Abstract ......................................................................................................................... I 
Acknowledgement ..................................................................................................... III 
Abbreviations ............................................................................................................. IV 
Table of Content ......................................................................................................... V 
List of Figures ............................................................................................................ IX 
List of Tables .............................................................................................................. XI 
 
Chapter 1  General Introduction .............................................................................. 1 
Chapter 2  Literature Review ................................................................................... 3 
2.1 Probiotics ............................................................................................................. 3 
2.1.1 Common physiology of probiotics ............................................................ 4 
2.1.2 Applications of probiotics ......................................................................... 5 
2.2 Function of probiotics .......................................................................................... 6 
2.2.1 Overview of probiotic functions ............................................................... 6 
2.2.2 Antimicrobial activities ............................................................................. 6 
2.3 Safety of Probiotics .............................................................................................. 9 
2.3.1 Clinical infections ..................................................................................... 9 
2.3.2 Safety Guidelines for probiotics ............................................................. 10 
2.4 Lactobacillus reuteri .......................................................................................... 11 
2.4.1 Historical background ............................................................................. 11 
2.4.2 Morphology ............................................................................................. 11 
2.4.3 Ecology ................................................................................................... 11 
2.4.4 Biochemistry ........................................................................................... 12 
2.4.5 Antimicrobial activity of Lactobacillus reuteri ...................................... 15 
2.4.5.1 Reuterin ............................................................................................ 15 
2.4.5.2 Reutericin ......................................................................................... 17 
2.4.5.3 Reutericyclin .................................................................................... 17 
2.4.6 Other functions of Lactobacillus reuteri ................................................. 18 
Table of Content 
 VI 
2.4.7 Production of reuterin ............................................................................. 18 
2.4.8 Safety of Lactobacillus reuteri ................................................................ 21 
2.4.9 Applications of Lactobacillus reuteri ..................................................... 22 
2.5 Lactobacillus reuteri DPC16 ............................................................................. 23 
2.5.1 Origin and identification ......................................................................... 23 
2.5.2 Previous studies on Lactobacillus reuteri DPC16 .................................. 23 
2.6 Hypotheses ......................................................................................................... 24 
 
Chapter 3  Antimicrobial activity of Lactobacillus reuteri DPC16 cell-free 
supernatants against selected food borne pathogens ........................ 26 
3.1 Introduction ........................................................................................................ 26 
3.2 Materials and Methods ....................................................................................... 28 
3.2.1 Growth of pathogen cultures ................................................................... 28 
3.2.2 Preparation of DPC16 cell-free supernatants .......................................... 29 
3.2.3 Primary antimicrobial assay of DPC16 supernatants .............................. 31 
3.2.4 Dose response test ................................................................................... 31 
3.2.5 A time course investigating the antimicrobial activity of DPC16 
supernatants ............................................................................................. 32 
3.2.6 An antimicrobial efficiency test using MRSg ......................................... 32 
3.2.7 Viability of DPC16 resting cells in glycerol-fermenting cultures ........... 32 
3.2.8 Statistical analysis ................................................................................... 33 
3.3 Results ................................................................................................................ 34 
3.3.1 The pH values of DPC16 cell-free supernatants ..................................... 34 
3.3.2 Primary antimicrobial assay against selected pathogens ........................ 34 
3.3.3 Dose response test ................................................................................... 39 
3.3.4 A time course investigation of DPC16 antimicrobial activity on pathogen 
growth ..................................................................................................... 43 
3.3.5 An antimicrobial efficiency test on MRSg .............................................. 48 
3.3.6 Viability of DPC16 resting cells in glycerol-fermenting cultures ........... 49 
3.4 Discussion .......................................................................................................... 51 
 
 
 
Table of Content 
 VII 
Chapter 4  Kinetics of Lactobacillus reuteri DPC16 growth and in situ reuterin 
production in a two-step fermentation process ................................. 57 
4.1 Introduction ........................................................................................................ 57 
4.2 Materials and Methods ....................................................................................... 59 
4.2.1 Culture preparation.................................................................................. 59 
4.2.2 Growth curve of L. reuteri DPC16 in pre-reduced MRS broth .............. 59 
4.2.3 Measurement of DPC16 dry matter by freeze-drying ............................. 59 
4.2.4 Colorimetric determination of glycerol and reuterin .............................. 60 
4.2.4.1 Glycerol ............................................................................................ 60 
4.2.4.2 Reuterin ............................................................................................ 61 
4.2.5 Relationship between reuterin and the antimicrobial activity in DPC16 
supernatants from glycerol fermentation ................................................ 62 
4.3 Results ................................................................................................................ 62 
4.3.1 Viable cell enumeration and pH measurement of DPC16 culture .......... 62 
4.3.2 Growth of L. reuteri DPC16 in MRS under anaerobic condition ........... 63 
4.3.3 Bioconversion of glycerol and yield of reuterin from biomass............... 65 
4.3.4 Reuterin and antimicrobial activity ......................................................... 66 
4.4 Discussion .......................................................................................................... 68 
 
Chapter 5  Evaluating the impacts of Lactobacillus reuteri DPC16 on mucin 
degradation and on the growth of other probiotics, in vitro ............. 73 
5.1 Introduction ........................................................................................................ 73 
5.2 Materials and Methods ....................................................................................... 76 
5.2.1 The effect of DPC16 supernatants on growth of the selected probiotic strains
 ................................................................................................................. 76 
5.2.2 Mucin degradation .................................................................................. 77 
5.2.2.1 Mucin purification ............................................................................ 77 
5.2.2.2 Basal medium for anaerobic cultures ............................................... 77 
5.2.2.3 Bacterial cultures .............................................................................. 78 
5.2.2.4 Mucin degradation assays ................................................................ 79 
5.3 Results ................................................................................................................ 80 
5.3.1 The effects of DPC16 supernatants on growth of the selected probiotic 
strains ...................................................................................................... 80 
5.3.2 Degradation of mucin in liquid media .................................................... 83 
Table of Content 
 VIII 
5.3.3 Degradation of mucin on agarose plate ................................................... 84 
5.4 Discussion .......................................................................................................... 85 
 
Chapter 6  General discussions and conclusion .................................................... 88 
References .................................................................................................................. 92 
Appendices ................................................................................................................ 110 
Appendix 1  Ingredients of cultural growth media .................................................. 110 
Appendix 2  Raw data and statistics ......................................................................... 111 
Appendix 3  Standard curves for colorimetric assays of glycerol and reuterin ....... 114 
 
List of Figures 
 IX 
List of Figures  
Figure 2.1  Heterofermentation of glucose by Lactobacillus reuteri in phosphoketolase 
pathway ..................................................................................................  13 
Figure 2.2  Lactobacillus reuteri production of 3-HPA during glycerol fermentation14 
Figure 2.3  Chemical dehydration of 3-HPA (reuterin) to acrolein, followed by further 
oxidation to 1,3-propanediol .................................................................... 20 
Figure 3.1  The pH values of MRSg and SGF measured during secondary fermentation 
with glycerol............................................................................................. 34 
Figure 3.2  Primary antimicrobial tests of MRSc and FZMRSc, and their pH adjusted 
counterparts. ............................................................................................. 35 
Figure 3.3 Primary antimicrobial test of MRSg harvested during a secondary 
fermentation ............................................................................................. 38 
Figure 3.4  Post-treatment viability test of pathogens treated with MRSg harvested 
from selected time points during secondary fermentation with glycerol. 38 
Figure 3.5  Primary antimicrobial test of SGF harvested during secondary 
fermentation ............................................................................................. 38 
Figure 3.6  Dose response of original MRSc against pathogens ................................ 40 
Figure 3.7  Dose response of original FZMRSc against pathogens. ........................... 41 
Figure 3.8  Dose response of original MRSg-8h against pathogens. .......................... 42 
Figure 3.9  Dose response of SGF-2h against pathogens ........................................... 42 
Figure 3.10 A time course of original MRSc treatment, in minimum effective dose, 
against selected pathogens.. ..................................................................... 44 
Figure 3.11 A time course of original FZMRS treatment, in minimum effective dose, 
against selected pathogens ....................................................................... 45 
Figure 3.12 A time course of MRSg treatment, in minimum effective dose, against 
selected pathogens .................................................................................... 46 
Figure 3.13 A time course of undiluted SGF treatment against S. Typhimurium and S. 
aureus ....................................................................................................... 46 
Figure 3.14 A time trend of cells viability of L. reuteri DPC16 resting cells in batch 
culture incubation of glycerol supplemented media. ............................... 50 
 
List of Figures 
 X 
Figure 4.1  Correlation curve of OD620 and the numbers of viable cells in a DPC16 
culture incubated in MRS for 20h ............................................................ 62 
Figure 4.2  Growth curve of DPC16 in pre-reduced MRS during anaerobic incubation  
at 37°C ...................................................................................................... 63 
Figure 4.3  Correlation curve of OD620 and CDW of DPC16 culture incubated in MRS 
for 20h. ..................................................................................................... 64 
Figure 4.4  Time course of L. reuteri DPC16 resting cells bioconversion of glycerol to 
reuterin in MRSg and SGF. ...................................................................... 65 
Figure 4.5  Production rate of reuterin during incubation of DPC16 in glycerol-MSR 
broth under standardised conditions. ....................................................... 66 
Figure 4.6  Antimicrobial activity of MRSg, expressed as concentration of reuterin, 
exhibited during the secondary fermentation of glycerol in MRS broth. 67 
Figure 5.1  Growth curves of probiotic strains in MRS during anaerobic incubation at 
37°C ......................................................................................................... 80 
Figure 5.2  Effects of MRSc, FZMRSc and their pH-adjusted counterparts on the 
growth of selected probiotic cultures ........................................................ 81 
Figure 5.3  Effects of MRSg, SGF and pH-adjusted MRSg on the growth of selected 
probiotic cultures ...................................................................................... 82 
Figure 5.4  A time course of probiotic strains treated with and without MRSg-8h or its 
pH-adjusted counterpart ........................................................................... 82 
Figure 5.5  Growth of potential probiotic cultures and faecal flora cultures in basal 
medium supplemented with designated carbohydrate sources ................ 83 
Figure 5.6  Degradation of mucin on agarose plate supplemented with PGM only and 
PGM with glucose. ................................................................................... 84 
 
 
 
 
 
List of Tables 
 XI 
List of Tables 
Table 3.1  Summary of DPC16 cell-free supernatants derived from various cultural 
media .......................................................................................................... 30 
Table 3.2  Antimicrobial activity of the MRSg (non-pH-adjusted), from selected time 
points during incubation, against target pathogens. ................................... 36 
Table 3.3  The lowest effective dose of each selected original supernatant (non-pH 
adjusted) against target pathogens. ............................................................ 43 
Table 3.4  A statistical analysis of pathogen growth rate with and without treatments 
from the designated DPC16 supernatants .................................................. 47 
Table 3.5  A statistical analysis comparing the number of total pathogen cells at the of 
the incubation, between pathogens treated with respective DPC16 
supernatants and the untreated controls ..................................................... 48 
Table 3.6  Sensitivity of pathogens to MRSg-8h treatment ........................................ 49 
Table 5.1  Ingredients of basal medium for mucin degradation assay. ....................... 77 
Table 5.2  The final pH value of cultures incubated in various media comparing with 
their original culture which indicate the starting pH values. ..................... 84 
 
 
 
 
Chapter 1                                            General Introduction 
 1 
Chapter 1 
General Introduction 
Modern consumers are increasingly interested in their personal health, and this elevates 
their selection of the foods they eat beyond taste and attractiveness to a new level of being 
healthy and safe (Puupponen-Pimia et al., 2002). There is accumulating scientific 
evidence to support the concept that the maintenance of healthy gut microflora can 
provide protection against gastrointestinal disorder (Vanderhoof and Young, 1998; 
Salminen et al., 1998 b; Heselmans et al., 2005; Niv et al., 2005). Probiotics with 
perceived health benefits have long been used in the food industry and now have gained 
greater interest in their potential to confer enhanced health and well-being for humans. 
The global market for probiotics products has entered an exponential phase of growth 
(BCC Research, 2005; Amagaze, 2008; Saxelin, 2008). Probiotic consumption in dairy 
products and the awareness of their health importance have a long history in New 
Zealand. The probiotic research focused on developing novel health-enhancing strains 
for New Zealand dairy industry has now stepped into a blooming era (Crittenden et al., 
2005).  
Lactobacillus reuteri DPC16 is a New Zealand patented probiotic strain (Shu and Liu, 
2008), and has been intensively studied for function and production by Bioactive 
Research New Zealand Limited (BRNZ). Preliminary research has shown 
health-enhancing effects including anti-infection and immuno-modulation (Liu et al., 
2004 a, b, c). Microencapsulation of live bacteria cells was also investigated, and it was 
found that microencapsulated DPC16 maintained good viability when incorporated into 
food ingredients (such as colostrum, whey protein, skim milk, propolis, seafood and 
plant extracts), hence process optimization using microencapsulation to extend shelf-life 
for products supplemented with this culture has been investigated (Joshi, 2005; Chang, 
2006; Yin, 2007; Chen, 2007). Additionally, an industrial application has recently been 
examined, which involves incorporating DPC16 culture into modified atmosphere 
packaging (MAP) to control seafood pathogens and to extend shelf-life of seafood 
products (Lu, 2007).  
However, to validate a probiotic concept, more characterisation of this novel strain 
remains to be done. For example, to evaluate the probiotic performance, a complete 
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antimicrobial assessment of this strain is essential. A previous study has shown that L. 
reuteri DPC16 has an antimicrobial activity against common food borne pathogens 
when co-cultured in modified MRS broth, and subsequent spent culture analysis 
revealed that such antimicrobial activity was non-proteinaceous, active at a wide range 
of pH values, insensitive to hydrogen peroxidase, and heat labile (Lu, 2007). These have 
all suggested the involvement of reuterin, a unique potent antimicrobial substance 
produced by L. reuteri species. However, in-depth investigations on DPC16 
antimicrobial activity, such as establishing minimum inhibitory concentrations (MICs) 
and the way in which the reuterin potentially affects the growth kinetics of these 
pathogens have not been done. In addition, specific reuterin production kinetics of this 
strain during utilisation of glycerol is still unknown. Lastly, but most importantly, there 
has been no attempt made to assess the safety of this novel strain in human consumption 
in terms of its effect on the growth of other normal gut microflora and its potential to 
compromise the barrier function of the gastrointestinal (GI) epithelial mucus. According 
to the International Safety Guidelines (Mattila-Sandholm, 1999a; Mattila- Sandholm et 
al., 1999b), these safety assessments are critical for validation towards probiotic 
concept. 
This research was built on previous findings on Lactobacillus reuteri and conducted as a 
continuing exploration focusing on fulfilling the above gaps. The main objective of this 
study was to provide evidence as partial contribution to the validation of this novel 
strain as a probiotic. The scope of this research covered the following: 
 Antimicrobial activity of extracellular metabolites presented in cell-free supernatant 
against selected pathogens and other members of normal intestinal microflora. 
 In vitro reuterin productivity and its relationship with corresponding antimicrobial 
activity. 
 Safety as assessed by mucin-degradation against porcine gastric mucus, in vitro. 
The literature relating to general probiotics concepts, the L. reuteri species and its 
antimicrobial function and safety assessments are reviewed in Chapter 2. Background of 
the interested L. reuteri DPC16 strain was also introduced. Based on the literature, 
hypotheses were proposed and a series of experiments was designed and conducted to 
test these hypotheses and to fulfil ultimate objectives   of this thesis. 
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Chapter 2 
Literature Review 
2.1 Probiotics 
Probiotics is a term derived from the Greek, meaning “for life”. Nobel laureate Elie 
Metchnikoff formulated the probiotic concept approximately 100 years ago. He 
proposed that consumption of certain ‘lactic bacilli’ would be beneficial to humans by 
maximizing health-promoting activities of the gastrointestinal microbiota and 
minimizing their potentially harmful effects (Metchnikoff, 1907; Casas and Dobrogosz, 
2000). From then on, probiotics have been scientifically studied and its definition has 
evolved and emerged from the gradual progress of understanding. Lilley and Stillwell 
(1965) describe probiotics as substances secreted by one microorganism to stimulate the 
growth of another, as opposite to an antibiotic. Parker (1974) defined probiotics as 
organisms and substances which contribute to intestinal microbial balance, and he was 
the first to include microorganisms into the definition which is in the sense that it is 
used today. Later, Fuller (1989) recognized probiotics as “a live microbial feed 
supplement which beneficially affects the host (humans or animals) by improving its 
intestinal microbial balance”. Furthermore, the probiotics concept was broadened, as “a 
viable mono- or mixed- culture of microorganisms which applied to animal or man, 
beneficially affects the host by improving the properties of the indigenous microflora” 
(Havenaar and Huis in’t Veld, 1992). The definition of probiotics continues to be 
improved, and was recently made official by the Food and Agriculture Organization 
(FAO) and the World Health Organization (WHO) (Araya et al., 2001, 2002) as “live 
microorganisms which when administrated in adequate amounts confer a health benefit 
on the host”. Scientific findings are continuing, and the new challenge on the probiotics 
definition is that the beneficial effects do not have to come from viable probiotic cells; 
non-viable probiotics can also have health effects such as epithelial competitive 
exclusion, immune modulation and carcinogen binding in the host (Ouwehand and 
Salminen, 1998; Salminen et al., 1999). Nowadays, world-wide interest in probiotics is 
increasing, and with continuous accumulation of knowledge the probiotics concept will 
surely enter a new era. 
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2.1.1 Common physiology of probiotics  
Probiotic microorganisms are commonly from the bacterial genera of Lactobacillus and 
Bifidobacterium, which are also characterised as lactic acid bacteria (LAB). LAB are 
Gram-positive, non-sporulating, non-respiring, usually non-motile and catalase-negative 
bacteria (Wikipedia.org, 2008). LAB are able to adapt to grow under microaerophilic to 
strictly anaerobic conditions. However, they are nutritionally fastidious (heterotrophic), 
requiring carbohydrates, amino acids, nucleic acid derivatives and vitamins to maintain 
a sufficient viability (Aguirre and Collins, 1993; Klein et al., 1998; Konings, 2002). 
LAB with probiotic activity are generally from GI microflora (Naidu et al., 1999), 
which are acidoduric or acidophilic and share the common physiological characteristics 
of surviving low pH and/or bile in the GI tract (Fuller, 1989). 
An essential feature of LAB is to produce lactic acid as the main end-product (>50% of 
sugar carbon) of metabolism, during which ATP is generated for subsequent 
biosynthetic purpose (Axelsson, 1998). Typical LAB metabolism, in brief, occurs via an 
anaerobic or facultatively anaerobic fermentation process, where available carbohydrate 
is metabolised. At the end of glycolysis, the internally-generated pyruvate acts as a 
hydrogen acceptor, instead of oxygen, to be directly reduced by a by-product NADH to 
produce lactic acid and NAD+. The resulting co-enzyme NAD+ is then recycled back to 
glycolysis (Elliott and Elliott, 2005).  
However, variations in LAB metabolism exist due to strain-specific enzymes 
responsible for various metabolic pathways, and such metabolic flexibility has provided 
LAB with greater adaptation to their environment (Zaunmuller et al., 2006). Practically, 
LAB are grouped into obligate homo-, facultative hetero-, or obligate 
hetero-fermentative organisms according to the metabolic pathway they use to ferment 
carbohydrate and to the end-products synthesised (Casas and Dobrogosz, 2000; Annuk 
et al., 2003). The obligate homofermentative (OHOF) group (e.g. L. acidophilus, L. 
delbrueckii, L. helveticus, L. salivarius) use the Embden-Meyerhof pathway (EMP) and 
produce lactic acid exclusively as the end-product. The obligate hetero-fermentative 
(OHEF) group (e.g. L. brevis, L. buchneri, L. fermentum, L. reuteri) only metabolise 
through the phosphoketolase pathway, and produce significant amounts of other 
products such as ethanol, acetate and CO2 in addition to lactic acid (Arskold et al., 
2008). The facultative hetero-fermentative (FHEF) group (e.g., L. paracasei, L. 
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curvatus, L. plantarum, L. lactis, and L. rhamnosus) can use either the 
Embden-Meyerhof pathway or the phosphoketolase pathway (Kleerebezem et al., 2003). 
Additionally, various growth conditions (media composition, pH, temperature, and 
presence of oxygen) may as well significantly change the end-products by altering 
pyruvate metabolism and external electron acceptors (Axelsson, 1998; Annuk et al., 
2003). For example, LAB are able to adapt to utilise a variety of other substances as 
ultimate electron acceptors (e.g. carbon dioxide, nitrite, sulphate, glycerol, and organic 
compounds) and of producing a spectrum of metabolic end-products.  
2.1.2 Applications of probiotics  
Acid-producing probiotics have been extensively used and play an important role in 
various fermented foods and beverages for thousands of years, as early as 6,000 B.C 
(Ouwehand and Vesterlund, 2004). During the last twenty years, with accumulated 
scientific evidence of health-enhancing effects to human, probiotics have been 
increasingly incorporated into functional foods and health supplements (Fuller and 
Perdigon, 2003). In addition, modern processing technologies such as freeze-drying, 
particle immobilization and microencapsulation have provided assurance for consumers 
that probiotics will retain viability and functionalities not only during manufacturing but 
also during consumption in the GI tract (Fuller, 1997; Saarela et al., 2000; Chang, 2006; 
Yin, 2007). Probiotics are now available to consumers in forms of milk-based dairy 
products (e.g. yoghurts and cheese), tablets and freeze-dried powders. It is noteworthy 
that, with continuous progress in understanding probiotics, the focus of nutrition 
attributes has moved from homofermentative species (e.g. L. acidophilus) to 
heterofermentative species (e.g. L. casei, L. plantarum, L. lactis, L. rhamnosus and 
Bifidobacterium species), especially the obligate heterofermentative species such as L. 
reuteri which are major components of intestinal microflora and of more prominent 
efficacy (Speck et al., 1993; Casas and Dobrogosz, 2000; Annuk et al., 2003).  
 
 
Chapter 2                                               Literature Review 
 6 
2.2 Function of probiotics 
2.2.1 Overview of probiotic functions 
Probiotics are defined as possessing valuable factors contributing to the health and 
well-being of hosts, including humans. It is thought that consumption of a sufficient 
amount [more than 109 CFU (colony forming units) per day of probiotics will be 
sufficient to balance the human GI micro-ecosystem by replacing harmful pathogens 
and reinforcing the natural defence mechanisms (Ouwehand et al., 2002). The reported 
health benefits of probiotics include: 
 Physiological effects, including improvement of intestinal motility (Gibson et al., 
2003), alleviating colon disorder symptoms (Marteau et al., 1990; Motta et al., 1991; 
Mattila-Sandholm et al., 1999 b; Marteau et al., 2002; Saxelin et al., 2005), and 
reduction of serum cholesterol and lipids (Gilliland and Walker, 1990; Naidu et al., 
1999);  
 Antimicrobial effects such as competing for nutrients and adhesion sites with 
pathogens, lowering intestinal pH, producing short chain fatty acids (SCFA), and 
synthesizing extracellular bacteriocins (Gill, 2003);  
 Immuno-modulatory effects of positively stimulating both humoral and 
cell-mediated immunity responses. Proven effects include enhancing production and 
circulation of serum antibodies, augmenting secretion of cytokines, improving 
effectiveness of ingested vaccines and restoring immune function in immuno- 
compromised hosts (Perdigon and Alvares, 1992; Gill, 1998, 2003; Gill et al., 2000; 
Maassen et al., 2000; Ezendam and van Loveren, 2006).  
This review focuses on the antimicrobial effects of LAB cultures and their metabolites.  
2.2.2 Antimicrobial activities 
The antimicrobial activity of gut lactobacilli targets pathogens of both Gram-negative 
and Gram–positive type; and such function has been found to be very variable and 
strain-specific (Jacobsen et al., 1999). 
 
Chapter 2                                               Literature Review 
 7 
So far, reported antimicrobial mechanisms involve both the whole bacterial cell and the 
cellular metabolites. A physiological mechanism considers the whole bacterial cell in 
competing for available binding sites and nutrients with pathogens. LAB cells 
commonly express cell surface hydrophobicity and specific surface proteins to facilitate 
coaggregation with either cells of the same strain or related species and with the host 
epithelia (Wadstrom et al., 1987; Strus et al., 2001). These adhesive features provide 
steric hindrance against other microorganisms, help to compete for available nutrients, 
and allow extracellular LAB metabolites to have access to the host epithelial surface 
(Ouwehand and Salminen, 1998; Tannock, 1999). Hence, the host epithelial surface is 
protected with a mucosal-associated shield from a variety of harmful invasions. 
Additionally, some studies also reported that some Lactobacillus species exert in vitro 
antimicrobial activity by coaggregating with pathogens, and creating a large contact 
area between bacterial membranes, hence resulting in increased impact of LAB 
antimicrobial metabolites to the coaggregated pathogens (Reid et al., 1988; Drago et al., 
1997).  
The metabolites of LAB have shown a wide inhibitory spectrum against both 
Gram-positive and Gram-negative bacteria. Considering the large number of different 
groups of chemical compounds present in LAB metabolites, it is most likely that their 
antimicrobial activity is not attributable to one specific mechanism but to synergistic 
effects targeting various components of the cell. Possible composition of LAB 
metabolites include SCFA (e.g. lactate and acetate) which lower the local pH; 
strain-specific bacteriocins; hydrophobic organic compounds that allow partition 
through the phospholipid membrane; and strong oxidative agents such as hydrogen 
peroxide (Ouwehand and Vesterlund, 2004). Nevertheless, the general antimicrobial 
effect of LAB is due to the acid production, which reduces intestinal local pH and in turn 
limits the growth of pathogens. For example, with a dissociation constant (pK value) of 
3.86 for lactic acid and 4.75 for acetic acid, these acids are partially in their 
undissociated form at lower pH values. These undissociated organic acids are lipophilic 
and are able to penetrate the bacterial cell membrane, and at higher intracellular pH 
values they dissociate to produce hydrogen ions that interfere with essential bacterial 
metabolic functions (Ingram et al., 1956; Baird-Parker, 1980; Booth, 1985). Reports have 
shown that LAB-produced organic acids can work in combination to display a strong 
inhibitory activity against many food-borne pathogens, such as Salmonella 
Typhimurium, E. coli, Bacillus cereus, Clostridium botulinum, Clostridium perfingens, 
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Listeria monocytogenes, and Staphylococcus aureus (Goepfert and Hicks, 1969; Adams 
and Hall, 1988; Wong and Chen, 1988; Kao and Frazier, 1996; Alakomi et al., 2000; De 
Keersmaecker et al., 2006).  
Another important factor contributing to the overall inhibition efficacy is LAB 
bacteriocin, a strain-specific heterogeneous substance to inhibit competition for the same 
niche in the micro-ecological environment (Bennison, 2005). Bacteriocins are 
low-molecular weight, cationic, and amphiphilic molecules released extracellularly by 
predominately Gram-positive bacteria (Riley and Wertz, 2002; Ouwehand and 
Vesterlund, 2004). A widely accepted hypothesis for bacteriocin activity is that it firstly 
adsorbs to specific or non-specific receptors on the target cell surface, and then alters the 
membrane permeability, thus disturbing membrane transport, and finally inhibiting 
energy production (Jung, 1991; Nissen-Meyer et al., 1992). Bacteriocins are different 
from antibiotics in several ways: bacteriocins are ribosomally synthesised peptides, their 
modes of action are mainly membrane-active, and they have a narrow killing spectrum by 
influencing only closely-related species (Abee et al., 1995). Nowadays, many 
bacteriocins have been discovered, and they vary in spectrum of activity, mode of action, 
molecular weight, genetic origin and biochemical properties. Nisin is the best-known 
bacteriocin produced by Lactobacillus lactis, and has been approved for use in various 
industries throughout the world (Hurst, 1981). Other bacteriocins produced by LAB 
include lactacin from L. acidophilus, pediocin from Pediococcus acidilactici, and 
enterocin from Enterococcus faecium. However, fewer bacteriocins are produced by 
Bifidobacterium than by Lactobacillus species (De Vuyst and Vandamme, 1994). Even 
though bacteriocin has been widely used in food preservation and medical applications, 
they are still limited by their narrow spectrum of inhibition, and extrinsic parameters such 
as pH tolerance and thermostability.  
Furthermore, another group of smaller molecules has been reported to be associated with 
LAB antimicrobial activity. These are low molecular weight substances sharing the 
common characteristics of tolerance of low pH value, thermostability and exerting 
activity across a broad spectrum. These include the strong oxidative agent hydrogen 
peroxide generated through NADH oxidase and superoxide dismutase (Batdorj et al., 
2007); carbon dioxide from heterofermentation to fortify the anaerobic environment; and 
diacetyl (if citrate is fermented) which interferes with the Gram-negative bacterial 
utilisation of arginine (Ouwehand and Vesterlund, 2004). Amongst this group, a 
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newly-found substance with wide antimicrobial spectrum has caught particular attention 
and attracted intensive studies over the last decade. Reuterin, produced by 
GI-autochthonous L. reuteri through dissimilating glycerol, has been reported 
extensively as a potent antimicrobial agent against both Gram-negative and 
Gram-positive bacteria, and lower eukaryotic organisms including yeast, fungi and 
protozoa (Talarico et al., 1988; Axelsson et al., 1989; Chung et al., 1989; Glass et al., 
2004). Later in this chapter, a detailed review of reuterin will be covered in aspects of 
production, mode of action, and safety.  
Therefore, the antimicrobial activity of probiotics relies on multiple factors, and these 
factors may work synergistically to contribute to the overall efficacy. However, it is 
preferred that probiotics exert antimicrobial activity against only pathogens. As it is 
defined, probiotics should confer benefit to the host; and thus they should not introduce 
any adverse effects.  
2.3 Safety of Probiotics  
2.3.1 Clinical infections  
Given the long history of human consumption, LAB are generally regarded as safe 
(GRAS). Even though this longstanding observation remains as a sound safety record, 
occasional reports on certain strains of LAB in association with human clinical 
infections have been published (Bayer et al., 1978; Aguirre and Collins, 1993). The first 
case of lactobacilli-associated endocarditis was reported by Marschall (1938). And with 
the rapid development of medical science and technology during the last decade 
(1992-2001), 16 cases of lactobacilli endocarditis have been reported, and a few other 
clinical infections such as liver abscess, bacteraemia, neonatal sepsis, meningitis, 
pneumonia and urinary tract infection have also been documented (Bayer et al, 1978; 
Mackay et al., 1999; Rautio et al., 1999; Land et al., 2005). Most of the Lactobacillus 
strains isolated from clinical cases belong to the species of L. rhamnosus, L. casei, L. 
rhamnosus, and L. acidophilus (Abgrall et al., 1997) However, all reported infections 
were extremely rare instances, and the responsible strains are all frequent inhabitants of 
human indigenous intestinal flora. And also, these cases were found among 
immune-compromised populations with underlying disease or predisposing conditions. 
To date, there has been no report of clinical LAB infection in healthy people (Gasser, 
1994; Donohue, 2004).  
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Nevertheless, with the increasing range of novel strains being introduced to food and 
medical applications, the safety status of the new probiotics cannot be assumed 
(Donohue, 2004). Hence, a comprehensive assessment is essential to evaluate novel 
probiotics for safety status; also, a monitoring system is necessary to track any side 
effects that may arise.   
2.3.2 Safety Guidelines for probiotics 
In 1996, the European Union initiated a program of “Demonstration of Nutritional 
Functionality of Probiotic Foods” (Project PROBDEMO, Fair CT-96-1028), which 
provides guidelines and scientific verification for claims of probiotics and associated 
products (Mattila-Sandholm, 1999; Mattila-Sandholm et al., 1999). This program, 
together with the guidelines by FAO/WHO (Araya et al., 2001, 2002) and other 
published documents (Lee and Salminen, 1995; Donohue and Salminen, 1996; 
Salminen et al., 1996, 1998 a, 1998b, 1999; Adams, 1999; Saarela et al., 2000）has 
established a list of safety criteria for probiotics.  
Firstly, the candidate strain must have clear identity and be distinguished from other 
strains by well-established analytical techniques (e.g. 16S ribosomal RNA identification) 
(Salminen et al., 1999). Secondly, the probiotics must be compatible with the host 
intestinal environment, i.e. surviving, colonizing and being genetically stable through 
the host GI tract (Saarela et al., 2000). Thirdly, the probiotic efficacy on other members 
of the intestinal flora and interaction with the host must be determined. For instance, the 
potential probiotics must be non-pathogenic and non-mutagenic, must not deconjugate 
bile salt, must not possess enzymatic properties of detrimental degradation of epithelial 
mucus in the GI tract, and most of all are not associated with colon diseases (Marteau et 
al., 1995; Saarela et al., 2000; Zhou et al, 2001; Fernandez et al., 2005). Lastly, the 
probiotic strain must not carry horizontally transmissible antibiotic resistance genes 
(Salminen et al., 1998a; Saarela et al., 2000). Many lactobacilli naturally display a wide 
range of antibiotic resistance, but in most cases, such resistance is not of the 
transmissible type (Charteris et al, 1998). Above all, the probiotic strains are preferably 
from healthy individual origin of similar species, in other words, probiotics for human 
use are preferably isolated from the GI tract of healthy human (Saarela et al., 2000). 
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2.4 Lactobacillus reuteri  
2.4.1 Historical background   
Lactobacillus reuteri was recorded in scientific classifications of lactic acid bacteria as 
early as the beginning of the 20th century (Orla-Jensen, 1919), though at that time it was 
undistinguished from L. fermentum. In the 1960s, a German microbiologist Gerhard 
Reuter isolated L. reuteri from human faecal and intestinal samples, and subsequently 
separated it from L. fermentum and re-classified it as L. fermentum biotype II (Reuter, 
1965). Kandler et al. (1980) eventually identified L. reuteri as a distinct species based 
on phenotypical and genetic characteristics, and proposed it being a new species of 
heterofermentative lactobacilli. Later, modern technologies have further confirmed the 
identity and clearly separated the two species. Since 1980, L. reuteri has been classified 
as a distinct species in the Lactobacillus genus (Kandler et al., 1980). 
2.4.2 Morphology  
Lactobacillus reuteri strains are Gram-positive, lactic acid-producing bacteria, their 
cells are slightly irregular, bent rods with rounded ends, generally 0.7-1.0 x 2.0-3.0 µm 
in size (Kandler and Weiss, 1986), and occurring singly, in pairs and in small clusters. 
2.4.3 Ecology 
Lactobacillus reuteri is considered as one of the few true autochthonous lactobacilli 
presented regularly in host large intestine (Reuter, 2001). It has been isolated directly 
from the GI tract or faeces of humans, monkeys, chicken, turkeys, doves, pigs, lambs, 
cattle, dogs, and rodents (Mitsuoka, 1992a; Casas and Dobrogosz, 2000), and has been 
found to be a major component of Lactobacillus species found in all hosts. In addition, 
it is the only Lactobacillus species which is believed to have established a symbiotic 
relationship with all hosts (Casas and Dobrogosz, 2000). Therefore, all species of L. 
reuteri isolated from various hosts have exhibited probiotic efficacy to hosts, hence 
convincingly supporting the probiotic concept.  
In animals and humans, experiments have shown that L. reuteri is transmitted from 
mothers to newborn animals or infants during birth and the nursing process via mainly 
the mammary duct (Casas and Dobrogosz, 2000). Also, orally administrated L. reuteri 
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has been shown to survive gastric acid and bile salts through the stomach and upper 
intestine, bind to the gut mucus and epithelial cells, and colonise the host intestine 
(Reuter, 1965; Casas and Dobrogosz, 2000). However, L. reuteri strains isolated from 
different hosts exhibit host-specific colonization characteristics, some of which are not 
crossable (Molin et al., 1992; Casas and Dobrogosz, 1997). 
2.4.4 Biochemistry 
Lactobacillus reuteri belongs to the obligate heterofermentative group of lactobacilli, 
and uses the phosphoketolase-based metabolic pathway to utilise available 
carbohydrates (Axelsson, 1998; Casas and Dobrogosz, 2000). It can ferment glucose 
alone and produce lactate, ethanol and CO2 as end-products; but an essential 
characteristic of L. reuteri is its ability to utilise glycerol (Talarico et al., 1988; El-Ziney 
et al., 1998; Luthi-Peng et al., 2002 b) (Figure 2.1). When glycerol is added as a 
substrate, the end-products change to more acetate/less ethanol, and the NADH formed 
during glycolysis is reoxidized by glycerol rather than in the ethanol pathway (Talarico 
et al., 1990). In the process involving glycerol, L. reuteri takes the phosphoketolase 
pathway (PKP) to produce lactate; in parallel with lactate formation, glycerol 
successfully competes with acetylphosphate as a preferred terminal hydrogen acceptor 
to recycle NAD+, and this results in the release of the highly energetic acetylphosphate 
which is subsequently channelled into the acetate kinase reaction for more ATP 
production. As a consequence, this glycerol metabolism allows a higher ATP generation 
and greater acetate production, and ultimately a higher cell growth rate and more 
biomass are achieved (Talarico et al., 1988, 1990). Hence, it is more favourable for L. 
reuteri to utilise glycerol at the later stages of glycolysis. It should be noticed that 
glycerol utilisation is only initiated by completion of the first few steps of breaking 
down fermentable carbohydrates (e.g. glucose). Talarico et al. (1990) postulated that L. 
reuteri cannot grow on glycerol alone, so this favourable process can occur only in the 
presence of fermentable carbohydrates.  
At the end of this featured glycerol metabolism, a series of end-products, including 
SCFA and other organic compounds, were produced. Among these, 3-HPA (3- 
hydroxypropionaldehyde) has drawn the most attention, and has been found to be a 
potent antimicrobial substance. 3-HPA is also termed reuterin (Talarico et al., 1988). 
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Figure 2.1  Heterofermentation of glucose by Lactobacillus reuteri in phosphoketolase pathway, 
with alternative end-products of lactate, ethanol and 3-HPA derived 1, 3-propanediol. 
Abbreviations: G6P, glucose 6-phosphate; 6PG, 6-phosphogluconic acid; Ru5P, ribulose 
5-phosphate; Xu5P, xylulose 5-phosphate; G3P, glyceraldehyde 3-phosphate; AcetylP, acetyl 
phosphate; 3-HPA, 3-hydroxypropionaldehyde. Figure adapted from Talarico et al. (1990). 
Reuterin is excreted as an intermediate during glycerol dissimilation, although some are 
further reduced to 1, 3-propanediol (Figure 2.2). According to Talarico et al. (1990), the 
production of reuterin involves a two-step enzymatic reaction, where glycerol is firstly 
dehydrated by a cobalamin (Vitamin b12)-dependent glycerol dehydratase to produce 
reuterin; concomitantly NADH/H+ produced from glycolysis is oxidized to NAD+. 
Secondly, a partial amount of reuterin is further reduced by a NAD+-dependent 
oxidoreductase to 1,3-propanediol, leaving excess reuterin accumulating in solution. 
Both of the enzymes responsible for glycerol metabolism have been isolated, purified 
and characterised. It has been found that glycerol dehydratase from L. reuteri is strictly 
specific for glycerol, and consists of four subunits with an overall molecular weight of 
160 kDa; while the L. reuteri oxidoreductase is similar to those of other bacteria 
undertaking the same pathway in terms of structure and enzyme activity, and comprises 
four identical subunits (4.2 kDa each) with overall molecular weight of 180 kDa 
(Talarico et al., 1990).  
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Figure 2.2  Lactobacillus reuteri production of 3-HPA during glycerol fermentation. Three forms 
of 3-HPA co-exist in equimolar concentration in the aqueous solution forming the reuterin system, 
and with NAD-dependent oxidoreductase, 3-HPA monomers are further reduced to 1, 
3-propanediol. Figure adapted from Casas and Dobrogosz (2000).  
Lactobacillus reuteri is not the only species that is known to produce 3-HPA. Other 
bacteria including Gram-positive Bacillus amaracrylus (Voisenet, 1914, 1918), 
Clostridium perfringens (Humphreys, 1924), and Clostridium butyricum (Malaouia and 
Marczak, 2000); and Gram-negative Enterobacter agglomerans (Barbirato et al., 1996), 
Klebsiella pneumoniae (Slininger et al., 1983) and Citrobacter freundii (Mickelson and 
Werkman, 1940; Barbirato et al., 1996) have also been reported to utilise glycerol via 
the same pathway and produce intermediate 3-HPA (Sobolov and Smiley, 1960; 
Vollenweider and Lacroix, 2004; Martin et al., 2005). However, these other bacteria can 
only produce 3-HPA as a transient metabolite, which is immediately further reduced; 
whereas L. reuteri has shown the unique capability to retain more than the required 
3-HPA (Talarico et al., 1988, 1990). The exact mechanism of this accumulation is still 
not clear, but it may be due to a strain-specific enhancement in expression of certain 
gene(s) encoding for responsible enzymes.  
Therefore, L. reuteri is unique in its exclusively accumulating reuterin (3-HPA). This 
featured capability out-competes with other producing strains, and provides L. reuteri 
with a potent antimicrobial activity. 
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2.4.5 Antimicrobial activity of Lactobacillus reuteri 
Accumulated evidence has revealed probiotic efficacy of this universally indigenous 
species amongst various hosts, especially its strong antimicrobial activity. It has been 
found that L. reuteri cells can strongly adhere to host GI epithelia via specific binding 
mechanisms and specialised surface proteins (Wadstrom et al., 1987; Roos et al., 1999; 
Roos and Johnsson, 2002). This strong adhesion of L. reuteri has assured the exclusive 
competition capability against other microorganisms competing for the same niche, as 
well as a direct impact of secreted metabolites to the host enterocytes and the 
gut-associated immunocytes, hence positive modulation of the host’s mucosal defences 
can be achieved. This review focuses on the antimicrobial function of some of the L. 
reuteri metabolites.   
As introduced previously, L. reuteri produces lactate, acetate and perhaps a variety of 
other SCFA along the heterofermentative metabolism pathway. Although it is certain 
that the acids partially contribute to the overall antimicrobial activity, this part of the 
review puts emphasis on those reuteri-specific substances and associated activities 
which are reported as unique to this species.  
2.4.5.1 Reuterin  
Reuterin is a pH neutral, water soluble, low molecular weight substance, which is 
non-bacteriocin, and resistant to nuclease, protease and lipolytic enzymes. It is active at 
a wide range of pH value, and capable of inhibiting growth of a wide spectrum of 
microorganisms, but it is also labile to heat (100 degrees C. for 10 minutes) (Talarico et 
al., 1988; Axelsson et al., 1989; Dobrogosz and Lindgren, 1995; El-Ziney et al., 1999). 
Reuterin was the first low molecular weight antimicrobial substance from Lactobacillus 
species ever to be chemically identified (Talarico and Dobrogosz, 1989), and has been 
intensively studied and relatively well understood (Vollenweider et al., 2003). Reuterin 
has been shown to exist in solution as an equilibrium mixture of three chemical 
compounds derived from glycerol dissimilation, namely the 3-HPA (3-hydroxy- 
propionaldehyde) system, containing monomeric, hydrated monomeric and cyclic 
dimeric forms of 3-HPA (Talarico and Dobrogosz, 1989). Talarico and Dobrogosz (1989) 
were the first to chemically characterise reuterin. They reported on the basis of mass 
spectrometry that reuterin has a molecular weight of 148, which is double that of the 
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3-HPA monomer (MW=74), and this indicated that reuterin may predominantly exist in 
the dimeric form of 3-HPA. However, their NMR studies revealed that reuterin exists 
predominantly as a 3-carbon compound (either hydrate monomer or dehydrate monomer 
of 3-HPA) and to a lesser extent as a dimeric form. This conflict was recently 
re-investigated by Vollenweider et al. (2003), who analysed the composition of the HPA 
system using ESI-MS and 13C NMR, and reported that distribution of the three 
compounds forming the HPA system was concentration-dependent in aqueous solution. 
At high concentrations, the HPA system predominantly comprises HPA cyclic dimer; 
decreasing the HPA concentration increases the mole-fraction of HPA hydrate and 
decreases the mole fraction of cyclic dimer until reaching equilibrium at 1.2 M HPA. 
The monomeric form of HPA was never detected to exist in significant amounts and 
always co-existed with the HPA hydrate. Hence, the three forms of 3-HPA co-exist in 
equilibrium in aqueous solution, and it is hard to isolate a single form and claim a 
certain activity for it. It is better to recognise reuterin as an equilibrium mixture of 
3-HPA system, and presume that the three molecules work together to contribute to the 
perceived activity. 
The unique and most attractive feature of reuterin is its strong antimicrobial activity. It 
has been found that concentrations of reuterin in the range of 15-30 µg/mL effectively 
inhibit growth of Gram-negative and Gram-positive bacteria, yeasts, fungi, and protozoa; 
while much higher concentrations are required to kill lactic acid bacteria, including L. 
reuteri itself (Axelsson et al., 1989; Chung et al., 1989; Casas and Dobrogosz, 2000). 
Studies on reuterin’s mode of action have postulated that the hemiacetal structure may 
give rise to a reaction between the aldehyde group and the terminal hydroxyl group to 
produce a molecule bearing close resemblance to a pentose such as D-ribose. Hence, 
re-structured reuterin can be a D-ribose analogue able to compete with ribonucleotides 
for their ribose-recognition site(s) on ribonucleotide reductase, thus interfering with 
DNA synthesis by inhibiting the conversion of ribonucleotides to deoxyribonucleotides 
(Dobrogosz and Lindgren, 1995; Lindren and Dobrogosz, 1998). Alternatively, another 
proposal suggests that the hydroxyl and aldehyde group might react with sulfhydryl 
enzymes (e.g. thioredoxin and ribonucleotide reductase) and alter the enzyme 
functionality (Talarico and Dobrogosz, 1989).  
However, the exact range of thermostability of reuterin is still not clear. Early studies 
have reported that reuterin in culture solution rapidly undergoes transformation to 
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acrolein during thermal dehydration (60°C) (Pressman and Lucas, 1942; Sobolov and 
Smiley, 1960). Talarico and Dobrogosz (1989) also reported reuterin was heat-sensitive 
at the high temperature (280°C) present in a gas chromatography injector. Dobrogosz 
and Lindgren (1995) claimed, in their patent, that reuterin was heat-labile at 100 °C. 
Recently, Lu (2007) found that the antimicrobial activity of a reuterin-containing 
supernatant from L. reuteri DPC16 culture was heat-labile (80°C). A heat-unstable 
reuterin could be a hindrance to some applications in the food and packaging industry. 
2.4.5.2 Reutericin  
Some strains of L. reuteri are also known to produce reutericin 6, which is a cyclic class 
II bacteriocin that mainly targets Gram-positive bacteria and closely related 
Lactobacillus species (Kabuki et al., 1997). Reutericin 6 was first reported by Toba et al. 
(1991) as produced by a L. reuteri strain LA6, isolated from human infant faeces. 
Purified reutericin 6 was reported to be hydrophobic and have a molecular weight of 5.6 
kDa (Kawai et al., 2001). The antimicrobial activity of Reutericin 6 has been tested 
against commercial strains including L. acidophilus, L. delbrueckii subsp. bulgaricus 
and subsp. lactis, and found to be bacteriolytic. Similar to other bacteriocins, the 
antimicrobial mechanism of this extracellular protein is believed to be the formation of 
pores in the cell membrane of the target bacteria, causing membrane depolarization and 
efflux of small cellular components resulting in cell death (Kabuki et al., 1997; Kawai 
et al., 2001; Kawai et al., 2004). However, Reutericin 6 was also reported to be 
sensitive to proteolytic enzymes and low pH (pH 2-3) (Toba et al., 1991; Kawai et al., 
2004). It is nearly two decades since the discovery of reutericin, but there are still 
doubts and conflicts about this bacteriocin, and some published findings have failed to 
be reproduced. Furthermore, the heat-sensitivity of reutericin has not been reported.  
2.4.5.3 Reutericyclin  
Another low molecular weight compound isolated from L. reuteri species (strain 
LTH2584) is reutericyclin. It is a naturally occurring, amphiphilic, tetramic acid, and its 
optimal formation was observed between pH 4 and 5 (Holtzel et al., 2000). It has been 
reported to have bactericidal and bacteriostatic activity against many gram-positive 
species, but does not affect Gram-negative bacteria (Ganzle et al., 2000). The mode of 
action of reutericyclin is to act as a proton ionophore, translocating protons across the 
cell membrane and dissipating the transmembrane pH potential (Ganzle and Vogel, 
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2003). However, reutericyclin has not been identified in reuterin-producing L. reuteri 
strains (Ganzle, 2004).  
Thus, it can be considered that the overall antimicrobial efficacy of L. reuteri results 
from contributions of all the above factors. Amongst these factors, reuterin has drawn 
the most attention and has been believed to have the most potential for industrial 
applications. 
2.4.6 Other functions of Lactobacillus reuteri 
In addition to its outstanding antimicrobial activity, L. reuteri is also believed to have 
physiological influence in host GI environment. As previously introduced (section 
2.4.4), L. reuteri metabolises through the phosphoketolase pathway under the anaerobic 
conditions of the host GI tract. It is able to utilise a variety of substances as alternative 
electron acceptors in which may include potentially toxic compounds; and hence L. 
reuteri may also help with the intestinal detoxification and modulating the intestinal 
environment to be favourable for the host (Arskold et al., 2008). Furthermore, L. reuteri 
has also been used as an effective therapeutic agent to moderate acute diarrhoea among 
children and to significantly reduce the duration of watery diarrhoea among children 
suffering from rotavirus or bacterial diarrhoea (Shornikova et al., 1997 a, 1997b; 
Weizman et al., 2005). It may, also, reduce Helicobacter pylori infections (Mukai et al., 
2002). An animal trail has shown that L. reuteri (strain ATCC 55730) has a positive 
influence on the development of ileal tissue, thereby enhancing absorption of nutrients 
(Casas et al., 1998). Lastly, a strain of L. reuteri (ATCC 55730) has been shown to 
positively modulate immune responses in human GI tract (Valeur et al., 2004).  
In conclusion, the collected evidence suggests that L. reuteri can colonise the host, 
protect against invasive agents and toxins, secrete potent substances against harmful 
pathogens and positively interact with the host cells, hence offering a wide range of 
benefits to the host.  
2.4.7 Production of reuterin 
As introduced previously (section 2.4.4), reuterin production by L. reuteri occurs during 
a heterofermentative process in dissimilating glycerol involving a two-step enzymatic 
reaction. Talarico et al. (1988) introduced a two-step fermentation method using 
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concentrated L. reuteri resting cells in a condition–controlled secondary glycerol 
fermentation process to produce relatively pure reuterin, in vitro. El-Ziney et al. (1998) 
studied glucose/glycerol co-fermentation of L. reuteri, and reported that glucose had a 
repressing effect on reuterin production and only very low concentrations (glycerol at 
150 mM with glucose at 60 mM or 20 mM under batch or chemostat culture condition, 
respectively) were favourable to reuterin production. Luthi-Peng et al. (2002 b) had 
similar findings and concluded that the end-product of glucose/glycerol co-fermentation 
was directed by the glucose: glycerol molar ratio, and reuterin accumulation was 
favoured with such molar ratio at no greater than 0.33. If excess glucose was supplied, 
reuterin would be further reduced to 1,3-propanediol. Hence, the impact of glucose on L. 
reuteri glycerol fermentation is significant, and glycerol as a non-fermentable 
carbohydrate has to be coupled with a fermentable carbohydrate source to produce 
reuterin.  
However, due to variations among strains, some L. reuteri strains have been reported to 
produce and accumulate reuterin in glycerol-water during incubation. Luthi-Peng et al. 
(2002 a) used the two-step fermentation process introduced by Talarico et al. (1988) and 
compared reuterin production of L. reuteri ATCC53608 in growth medium (MRS) and 
non-growth medium (distilled water) both supplemented with glycerol. They reported 
that reuterin was produced in both media and reached a plateau after only 2h of 
secondary fermentation, and the reuterin production was higher when glucose was 
present. They also studied the effects of selected fermentation parameters (temperature, 
pH value, biomass, cell age and initial glycerol concentration) and determined an 
optimal fermentation condition for this strain to produce reuterin as incubation of 30 g/L 
dried L. reuteri resting cells in glycerol (200 mM)-water solution for 3h at 37°C. Under 
such conditions, they reported that 170 mM of reuterin was produced. Vollenweider et 
al. (2003) reported reuterin production from similar fermentation process by another L. 
reuteri strain SD2112, and they found that 45% of the initial glycerol concentration was 
converted into reuterin. The above glycerol-water fermentation to produce reuterin has 
provided major advantages in obtaining accumulated reuterin by simplifying the 
purification process and minimising contaminations from by-products. However, the 
ability to continue dissimilating in water seems to be highly strain-specific, and the 
exact mechanism by which L. reuteri cells reduce glycerol without the presence of 
glucose has never been reported.  
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So, in vitro production of relatively pure reuterin can be achieved by the application of 
concentrated L. reuteri resting cells in a condition–controlled secondary fermentation 
process with glycerol supplementation. But, which medium to use in the secondary 
fermentation remains a question, and this is highly dependent on the producing L. 
reuteri strain. Reuterin production in purer solutions of glycerol-water is preferred only 
if the producing strain has the required capability; otherwise reuterin is more likely to 
be accumulated in glucose-containing growth media with a molar concentration ratio of 
glucose: glycerol greater than 0.33.  
The detection and quantitative determination of reuterin has been reported to use a 
colorimetric method introduced by Circle et al. (1945), which is easy to conduct and has 
been proved to produce accurate result (Slininger et al., 1983; Talarico et al., 1990; 
Luthi-Peng et al., 2002 a, 2002 b; Vollenweider and Lacroix, 2004). This method 
measures a dehydration derivative of reuterin in a heated acid aqueous solution. Figure 
2.4 displays the schematic pathway of glycerol reduction to reuterin, reuterin 
dehydration to acrolein and further reduction of reuterin to 1,3-propanediol. It shows 
that intermediate reuterin can establish an equilibrium with acrolein in solution under 
designated non-physiological conditions. During this process, acrolein is reversibly 
produced as a dehydration derivative in equimolar concentrations to reuterin in heated 
acid aqueous solution; hence, by measuring the concentration of acrolien, the quantity 
of reuterin can be determined.  
 
 
 
 
Figure 2.3  Chemical dehydration of 3-HPA (reuterin) to acrolein, followed by further oxidation to 
1,3-propanediol. Adapted from Sauvageot et al. (2000). 
The in vivo production of reuterin still remains to be explored. It may be produced in the 
more distal anaerobic regions of the gut where sufficient amounts of glycerol may 
become available as a product of luminal microbial fermentations, digestion of luminal 
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fats, sloughed mucus and exfoliated epithelial cells (Casas and Dobrogosz, 2000), and 
auto-diffusion of endogenous plasma glycerol. Moreover, it has been proved that 
reuterin production and accumulation can occur under physiological conditions of pH 
value and redox potential similar to those in the small and large intestine (Chung et al., 
1989). However, the in vivo measurement of reuterin production has never been 
reported.  
2.4.8 Safety of Lactobacillus reuteri 
According to the probiotics safety guidelines mentioned in section 2.3.2, L. reuteri strains 
should meet certain criteria to be considered as safe, such as being distinguished by 
genetic identification, having no history of detrimental effect on the host, being able to 
survive passage through the host GI tract, and not carrying horizontally transmissible 
antibiotic resistance genes. Lactobacillus reuteri belongs to the Lactobacillus genus, 
which has a long history of safe usage across various food industries. Even though 
opportunistic clinical infections of lactobacilli exist, there are no such reports for L. 
reuteri or the previously-classified L. fermentum (Wolf et al., 1995). In addition, L. 
reuteri has been demonstrated, in vitro, to be able to resist pH 2.5 and 0.3% bile, and to 
adhere strongly to an intestinal epithelial model cell-line (Caco-2) indicating potential 
ability to colonise the host GI tract (Casa and Dobrogosz, 2000). Thirdly, a L. reuteri 
strain has been found, in a probiotics screening test, to display no adverse effect on 
normal GI bacterial residents (Jacobsen et al., 1999). And lastly, like many other species 
of LAB, plasmid-associated antibiotic resistance genes have been found in some of the L. 
reuteri strains from both animal and human origin (Vescovo et al., 1982; Sarra et al., 
1982; Tannock et al., 1994; Lin et al., 1996), however, there is no evidence that they are 
able to be transferred to other bacteria that intrinsically lack such resistance.   
Results from a series of animal trials, including chicken (Dobrogosz et al., 1991), turkeys 
(Edens et al., 1997), swine (Casas et al., 1998), pigs (Blanchard et al., 1998) and colitis 
rats (Fabia et al., 1993) have confirmed not only the safety of L. reuteri in animal feeds, 
but also that it possesses growth-promoting and therapeutic value to all tested animal 
hosts (Casas and Dobrogosz, 2000). 
Speck et al. (1993) first postulated that L. reuteri is safe to be used in the food industry 
and can be consumed as a supplement without adverse effect. In human studies, the first 
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clinical safety trial of L. reuteri was conducted in 1995 in Finland (Casas and Dobrogosz, 
2000). The strain was isolated from breast-milk of a healthy human female, and 
double-blind trials were conducted on infants aged from 6-36 months hospitalized with 
viral or bacterial infections. It was concluded that administration of L. reuteri was 
accompanied with a good GI colonization and had no adverse effect. Another trial 
conducted in Mexico with child subjects also confirmed that oral intake of L. reuteri was 
well tolerated and colonised in high numbers, with no significant difference amongst 
doses administered (Ruiz-Palacioz et al., 1996). Wolf et al. (1995, 1998) also 
demonstrated that the oral administration of L. reuteri was safe and well tolerated in both 
healthy and immunodeficient adult human subjects. Recently, Connolly (2004) 
summarised the clinical trials ever done on L. reuteri strain ATCC 55730 and claimed it as 
a clinically proven probiotic bacterium.  
The above animal studies and clinical trials indicate that L. reuteri is safe to use and free 
from side effects, even when administered in L. reuteri supplemented products. In 
addition to being safe, L. reuteri confers favourable physiological properties and 
therapeutic values for the host.  
2.4.9 Applications of Lactobacillus reuteri 
Information on L. reuteri as a functional food component and health supplement has 
been available for the two last decades. The main focus has been to take advantage of its 
significant efficacy in inhibiting enteropathogenic invasion, maintaining a health 
balance of host intestinal microflora, and reinforcing the host mucosal defence barrier 
and maintaining mucosal integrity.  
L. reuteri was first introduced into the human functional foods market in Sweden in 
1991 as a mixture of cultures (Bifidobacterium animalis, L. reuteri and L. acidophilus) 
in milk. From then on, L. reuteri has been incorporated into various food and drinks as a 
potent bioactive ingredient throughout the western world. Now, all clinically tested L. 
reuteri strains are available commercially as functional food ingredients (Casas and 
Dobrogosz, 2000). BioGaia, a company based on strong scientific research of L. reuteri, 
is a worldwide producer of L. reuteri-containing products from strains with clinically 
approved efficacy (Vollenweider, 2004; Wikipedia.org, 2007; BioGaia, 2008). L. reuteri 
is also reported to be a possible alternative to bio-feed in certain types of animal 
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farming, given its proven safe usage and significance in improving animal growth 
(Casas and Dobrogosz, 2000). It can be foreseen that potential replacement of 
antibiotics with host-specific probiotic feed in animal farming will largely reduce the 
threat of growing antibiotics-resistance. Recently, more attention has been put on the 
applications of purified reuterin. As a potent natural antimicrobial agent with low 
cytotoxicity, it has been used in sanitization of biological tissues (Sung et al., 2002; 
Chen et al., 2002; Liang et al., 2003), and treatment of food-borne pathogens as a 
microbial preservative (Daeschel, 1992; El-Ziney and Debevere, 1998; El-Ziney et al., 
1999; Kuleasan and Cakmakci, 2002; Arques et al., 2004). A very recent proposal 
incorporates reuterin into modified atmosphere packaging in food preservation (Lu, 
2007). 
2.5 Lactobacillus reuteri DPC16  
2.5.1 Origin and identification 
Lactobacillus reuteri DPC16 was originally isolated from faecal samples of a healthy 
Caucasian male by Bioactive Research New Zealand (BRNZ). A sugar fermentation 
profile established by using an API 50CH-L system (BioMerieux Inc.) was initially used 
to identify this strain in the Lactobacillus genus (Liu and Peng, 2007). In 2004, a 
fragment of 16S rRNA gene of this strain was sequenced (Lu, 2007), and the alignment 
in GenBank database revealed that this strain was affiliated to the Lactobacillus genus 
with 99.3-99.6% similarity to known species of L. reuteri, and at least 0.5% sequence 
differences in the genomic DNA from other L. reuteri strains. In addition, a 279 bp 
fragment was detected with a sequence corresponding to a gene encoding glycerol 
dehydratase in L. reuteri species. Hence, this DPC16 strain was identified as a novel L. 
reuteri strain, and registered for a patent by BRNZ in New Zealand (Shu and Liu, 
2008).  
2.5.2 Previous studies on Lactobacillus reuteri DPC16 
Since its isolation, several investigations have been conducted to understand the 
characteristics and health-promoting properties of this new L. reuteri strain. And also, 
fermentation, storage, and a large scale production process have been investigated. 
Previous studies have shown that L. reuteri DPC16 has antimicrobial potential against 
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Salmonella Typhimurium infection in mice (Liu and Chen, 2004c). Preliminary tests for 
immunity enhancement and resistance to rotavirus infection have also been reported 
(Liu and Chen, 2004 a, b). Recently, as certain commercialization approaches have been 
attempted, DPC16 cell integrity during microencapsulation was studied to evaluate 
optimal processing and storage conditions for this culture (Joshi, 2005; Chang, 2006; 
Yin, 2007; Chen, 2007).  
The most recent study (Lu, 2007) reported a strong antimicrobial activity of DPC16 
against common food borne pathogens when co-cultured in glycerol-supplemented 
MRS broth, and subsequent analysis revealed that such antimicrobial activity was 
extracellular, non-proteinaceous, active at a wide range of pH values, insensitive to 
hydrogen peroxidase, and heat labile. By excluding the potential contributions from 
physiological influences, SCFA, protein-associated reutericin and reutericyclin, the 
remaining potent antimicrobial activity has strongly suggested the presence and 
involvement of reuterin. However, further investigation and characterisation of this 
strain remains to be done, and more importantly the exploration of this strain’s safety 
status is still necessary.  
2.6 Hypotheses  
Based on the literature, several hypotheses were made towards the objectives. Firstly, 
this novel strain has been identified as one of the L. reuteri species, so it may have 
physiological characteristics of L. reuteri, including production of SCFA and reuterin. 
As tested in preliminary studies, this strain has inhibitory effects against selected 
pathogens. The first hypothesis was that this strain’s antimicrobial activity was due to 
either the SCFA, or the production of reuterin, or both. A dose response test and 
subsequent time course experiment using the determined minimum dose may reveal 
more information on the antimicrobial activity of this strain.  
Secondly, reuterin is known to be produced and accumulated in L. reuteri culture, and 
this strain has been identified to possess the gene responsible for glycerol reduction to 
reuterin, however, the optimal conditions for reuterin production are unknown. Thus, 
the secondary hypothesis was that this strain may have the ability to produce and 
accumulate reuterin in both growth medium (MRS) and non-growth medium 
(glycerol-water). By using a secondary fermentation method (Talarico et al., 1988; 
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Luthi-Peng et al., 2002 b) and a colorimetric detection technique (Circle et al., 1945), 
the production of reuterin can be measured and the level of reuterin concentration 
produced in different media can be compared. Further, by determining the biomass 
concentration, the specific rate of reuterin production can be obtained, and by 
incorporating these results with the characterised antimicrobial activity, a correlation 
between reuterin and its antimicrobial activity can be determined.  
Finally, because L. reuteri species is universally indigenous, it is hypothesised that this 
novel DPC16 strain has no adverse effects on the growth of other normal GI inhabitants. 
Interestingly, reuterin may have growth-stimulating effect on other probiotic bacteria, 
because it is structurally similar to methylglyoxal (bioactive ingredient in Manuka 
honey) which is proposed to stimulate growth of LAB at very low concentrations 
(Rosendale, 2007). Also, given that L. reuteri has the ability to strongly colonise host GI 
epithelia and there have been no safety concerns arising from either clinical trials or 
extensive applications, this strain of L. reuteri should not have any adverse effect on 
gastric or intestinal mucus in terms of mucinolytic activity, either.  
To test the above hypotheses, a series of experiments were designed using the methods 
in the literature and previous studies, with some modifications to ensure compatibility 
with the objectives. 
This thesis serves as a partial contribution towards the validation of the probiotic status 
claimed for this novel strain. Outcomes are expected to contribute as partial fulfilment 
of the characteristic profile of this strain with regards to health benefits and safety for 
human consumption and technological feasibility for commercialization.  
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Chapter 3 
Antimicrobial activity of Lactobacillus reuteri DPC16 cell-free 
supernatants against selected food borne pathogens 
3.1 Introduction  
With the increasing global concerns about public health and the abuse of antibiotics, 
there is a growing demand for the use of naturally occurring antimicrobial agents to 
treat pathogenic infections where antibiotic resistance has become a serious issue. 
Probiotics, commonly represented by LAB, are known to inhibit enteric pathogens 
resulting in maintenance of a healthy microbial balance in the host GI tract, and also are 
generally regarded as safe (GRAS) due to their long history of safe use. Antimicrobial 
activities of LAB are largely due to their production of organic acids (e.g. lactate, 
acetate, citrate and butyrate), ethanol, hydrogen peroxide, carbon dioxide, diacetyl, 
acetaldehyde and bacteriocins (Ouwehand and Salminen, 1998). These antimicrobial 
compounds can exert specific activities against both commensal organisms and 
pathogens. For example, the LAB-produced proteinaceous bacteriocins have specific 
inhibitory activity against closely-related probiotic species to prevent competition in the 
same niche (De Vuyst and Vandamme, 1994; Abee et al., 1995; Bennison, 2005). In 
contrast, pathogens are more sensitive to the organic acids produced during LAB 
fermentation of utilizable carbohydrates (Alakomi et al., 2000; De Keersmaecker et al., 
2006). Additionally, some LAB strains have more strain-specific antimicrobial activity 
against certain or a specific group of pathogens, while some other possess the capability 
to produce special substances against a broad range of pathogens. 
Lactobacillus reuteri is known for its potent antimicrobial activity against a wide 
spectrum of microorganisms including both Gram-negative and Gram-positive bacteria, 
yeasts, fungi, and protozoa (Axelsson et al., 1989). Besides the general acidic effect 
from SCFA, a series of other specific substances have also been reported to contribute 
to the overall antimicrobial activity of this species. These include the proteinaceous 
reutericin and reutericyclin, which are L. reuteri-specific bacteriocins; as well as 
reuterin, a hydroxyl-propanal produced from glycerol in culture media. Amongst these 
antimicrobial factors, reuterin has been of much interest and numerous studies have 
been done to investigate this potent antimicrobial compound.  
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Preliminary study (Lu, 2007) on this particular strain has shown that DPC16 can exert a 
strong antimicrobial activity against selected Gram-positive and Gram-negative 
pathogens when co-cultured in glycerol containing MRS broth; and this activity, from 
DPC16 secreted metabolites, was non-proteinaceous, active at a wide range of pH 
values, insensitive to hydrogen peroxidase, and heat labile. These data have provided 
evidence for the presence of reuterin in DPC16 culture. However, further 
characterisation of this DPC16 antimicrobial activity was left unfinished, and the 
capability of DPC16 to exhibit similar antimicrobial activity when it was cultured in 
glycerol-water was not demonstrated. 
The antimicrobial investigation in this study was built on the previous findings, and 
focused on profiling the antimicrobial effects of DPC16 cell-free supernatants from a 
variety of media, especially ones from glycerol-supplemented media. Makras et al. 
(2006) introduced a kinetic method to study the antimicrobial activity of six lactobacilli 
against pathogenic Salmonella Typhimurium in batch fermentation under controlled 
conditions. In their study, the inhibitory activity of a cell-free culture supernatant of 
each probiotic strain was studied in a kinetic analysis. By studying the production 
kinetics of antibacterial activity and controlling the pH value during the antimicrobial 
assay, they were able to distinguish between the acid effect and effects attributed to 
other low-molecular-mass inhibitory metabolites produced. Additionally, by monitoring 
several kinetic parameters such as glucose utilisation, lactic acid production and specific 
growth rate of each culture, the antimicrobial activity of each Lactobacillus strain was 
comprehensively characterised.  
In addition to the conventional antimicrobial assay, a similar kinetic approach based on 
the above method was carried out to understand the development of antimicrobial 
activity of DPC16 cell-free supernatants from incubations involving glycerol.  
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3.2 Materials and Methods 
3.2.1 Growth of pathogen cultures 
The pathogenic Escherichia coli O157:H7 strain 2988 (E. coli), Salmonella enterica 
serovar Typhimurium ATCC1772 (S. Typhimurium), Listeria monocytogenes Scott-A 
ATCC49594 (L. monocytogenes) and Staphylococcus aureus ATCC2592 (S. aureus) 
were kindly provided by BRNZ. These strains were stored as 30% glycerol stocks at 
-80°C. For activation, 1% (v/v) of each thawed pathogen stock was inoculated 
aseptically into 10 mL BHI broth (BBL, USA) and incubated at 37°C for overnight (A 
detailed composition of BHI broth is shown in Appendix 1). Subsequently, the activated 
pathogens were sub-cultured in BHI broth for another 18h and the subcultures were 
used as master inocula for subsequent assays (these master inocula were always freshly 
made from stock prior to assay).   
Growth of pathogens followed the method described by Lu (2007), with enumeration 
using a drop-plate technique introduced by Herigstad et al. (2001). Briefly, 1% (v/v) of 
each pathogen master inoculum was inoculated in BHI, in triplicate, and incubated 
aerobically with shaking (250 RPM; orbital OS10 control, YellowLine; USA) at 37°C 
for 18h. After incubation, each pathogen culture was decimally diluted with 0.1% (w/v) 
sterile peptone water (trypticase peptone; BBL, USA) up to 107-fold, and peptone water 
alone was used as control. Dilutions of 105-, 106-, and 107-fold were used to count viable 
cells of each pathogen. Aliquots of each dilution of every pathogen (10 µL) were 
dropped, in triplicate, onto a BHI agar plate [1.5% (w/v)]. Peptone water alone was used 
as a control on the same BHI agar plate. All inoculated plates were allowed to dry in a 
laminar airflow cabinet before incubation at 37°C for 24h. Colonies were counted on a 
digital colony counter (SC6, Stuart Scientific; UK), and viable cells were recorded as 
the mean of triplicates for each countable dilution. Based on this enumeration, a culture 
dilution containing approximately 104 CFU/mL was prepared for each pathogen, as a 
subculture inoculum capable of producing a full growth curve (with a defined length of 
lag phase) during incubation.  
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3.2.2 Preparation of DPC16 cell-free supernatants 
Lactobacillus reuteri DPC16 was provided by BRNZ in 30% glycerol stock stored at 
-80°C. Firstly, the thawed stock culture was activated by propagating [1% (v/v)] in 10 
mL MRS broth (Difco, Michigan, USA) at 37°C overnight (A detailed composition of 
MRS broth is shown in Appendix 1). The activated stock culture was then aseptically 
streaked onto MRS agar [1.5% (w/v) agar], and incubated for 24h at 37°C. This 
subculture was then stored at 4°C as a DPC16 master plate until use, and this seeded 
storage was kept for a maximum period of one month.  
The cultivation method of this strain used in previous study (Lu, 2007) was followed in 
the present work, with some modifications. To grow the culture, a single colony with 
typical morphology from the DPC16 master plate was isolated and inoculated into a 
pre-reduced [containing 0.05% (w/v) L-cysteine and keeping standing for overnight] 
MRS broth, and incubated anaerobically*
The cell pellet was used for secondary fermentations to prepare supernatants with 
glycerol supplementation. The procedure was based on the methods described by 
Luthi-Peng et al. (2002 b) in preparation of supernatant from glycerol-MRS 
fermentation, and Talarico et al. (1988) in preparation of supernatant from 
glycerol-water fermentation. Briefly, the cell pellet was washed twice with 1 x 
 (Gaspak system, BBL; USA) at 37°C for 20h 
(unless otherwise stated, this method was standardized for preparation of all probiotics 
cultures throughout this thesis). After incubation, the DPC16 culture was centrifuged 
(refrigerated centrifuge 5810R, Eppendorf, Germany) at 4,000 x g for 10 min at 4°C. 
The supernatant was filter-sterilised through a 0.2 µm syringe-end filter system 
(Minisart, Sartorius; Germany) to remove any remaining cells, and this cell-free 
supernatant was designated as MRSc (derived from pre-reduced MRS broth) and was 
stored at 4°C until the time of use (maximum storage one month). Additionally, part of 
MRSc was subjected to freeze-drying (FreeZone Plus Cascade Console Systems, 
Labconco; USA) and the freeze-dried MRSc was aseptically re-dissolved to the 
previous volume in distilled water, designated as FZMRSc. FZMRSc was subsequently 
filter-sterilized and stored at 4°C until use (maximum storage one month).  
                                                        
*The anaerobic condition applied throughout this thesis is provided by Gaspak® Gas generating reagents 
contained in a BBL® sachet, which consists of inorganic carbonate, activated carbon, ascorbic acid. These 
reagents could produce a gas mixture with 15% or more CO2 in humidified atmosphere. The anaerobic 
environment is indicated by an indicator strip coated with methylene blue solution.   
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Phosphate Buffer Saline solution (PBS, pH 7.2; Difco, USA) to ensure removal of 
metabolites, and then starved in 0.9% saline solution at 37°C for 30 min. Then, the 
washed and starved resting cells were harvested and subsequently freeze-dried. In the 
freeze-drying process, the cells were frozen at -80°C for 48h, and then lyophilized under 
pressure of 0.33 mbar on a bulk tray freeze-drier (FreeZone Plus Cascade Console 
Systems, Labconco; USA) for another 48h. The freeze-dried cells were then 
re-suspended in either pre-reduced MRS or distilled water to half of the original volume 
from which they were harvested (concentrated at twice their original concentration). 
The pre-reduced MRS was supplemented with 360 mM of sterile glycerol, where the 
glycerol to glucose molar concentration ratio was greater than 3:1 (MRS broth contains 
110 mM of glucose). The distilled water was supplemented with 250 mM glycerol. The 
resting cells suspensions were incubated anaerobically at 37°C for up to 20h in 
glycerol-MRS, and up to 8h in glycerol-water. At set time intervals, samples of each 
suspension were harvested, cooled immediately on ice and centrifuged (4,000 x g for 10 
min at 4°C). The sampled supernatants were collected, filter-sterilized and stored 
immediately at 4°C until subsequent antimicrobial assays. The supernatant series 
obtained from secondary fermentation of glycerol-MRS was designated as MRSg, while 
the supernatant series derived from glycerol-water was designated as SGF (sole glycerol 
ferment). These supernatants were kept for a maximum of one month. Table 3.1 
summaries the supernatants prepared as above.  
Table 3.1  Summary of DPC16 cell-free supernatants derived from various cultural media   
Cell-free supernatants (CFS) Source 
MRSc MRS pre-reduced with 0.05% L-cysteine  
FZMRSc Water (aqueous solution of freeze-dried MRSc) 
MRSg Glycerol-MRS 
SGF Glycerol-water 
Finally, the pH values of the above supernatants were determined. MRSc and FZMRSc 
were measured using a pH meter (Orion, Thermal Scientific; USA) at room temperature. 
For MRSg and SGF, which were smaller volumes, pH values were measured using a 
portable pH meter (pH pen KS732, Shindengen; Japan). Where noted, the pH 
adjustments of the DPC16 supernatants were carried out by neutralising them to pH 6.5 
using 0.1 M sodium hydroxide at room temperature prior to testing the antimicrobial 
activity
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3.2.3 Primary antimicrobial assay of DPC16 supernatants  
Cell-free supernatants (with and without pH adjustment) of MRSc, FZMRSc, MRSg, 
and SGF were primarily tested for any antimicrobial activity against selected 
food-borne pathogens. Briefly, an aliquot of each supernatant (20 µL) was added, in 
triplicate, into 180 µL of BHI broth containing 20 µL of each pathogen (approximately 
104 CFU/mL), in 96-well microtitre plates. Negative controls contained pathogen 
cultures only, whereas positive controls replaced supernatant with commercial 
antibiotics (100 IU penicillin and 10 µg/mL streptomycin, Sigma; USA). To avoid 
contamination, each microtitre plate was inoculated with only one strain of pathogen. 
The inoculated microtitre plates were incubated aerobically at 37°C with shaking (250 
RPM) for 18h. The antimicrobial activity of each supernatant was quantitatively 
determined by turbidity development (OD620) of pathogens measured on a microtitre 
plate reader (Multiskan, Thermo Scientific; Finland), in comparison with untreated 
controls. Unless otherwise stated, this method and experimental conditions were 
standardised for all antimicrobial assays throughout this thesis. 
3.2.4 Dose response test 
Based on results from the primary antimicrobial test, the supernatants with significant 
antimicrobial activities were selected, binary-diluted, and subsequently tested for dose 
responses against respective pathogens. In brief, the binary dilution of each selected 
supernatant was prepared up to 512-fold in 96 well microtitre plates. Then, each dilution 
(20 µL) from every selected supernatant was added, in triplicate, into BHI broth (180 
µL) containing 104 CFU/mL of each target pathogen (20 µL). Controls without 
supernatants were included. All microtitre plates were incubated and the OD values 
were measured as described above. The lowest effective dose of each selected 
supernatant, which still significantly inhibited the growth of target pathogens, was 
hence determined, and this dose was used in a following time course experiment to 
further study its antimicrobial activity.  
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3.2.5 A time course investigating the antimicrobial activity of DPC16 
supernatants 
A time course was designed to test pathogen growth in the presence of the above 
DPC16 supernatants with known minimum effective doses. In this time course, the OD 
value of each treated pathogen was serially measured at 3h intervals during a 21h 
incubation at 37°C under aerobic conditions. Untreated pathogens were used as a 
control.  
3.2.6 An antimicrobial efficiency test using MRSg 
DPC16 cell-free supernatant, MRSg (undiluted and pH-unadjusted), was further studied 
by a viable cell count assay to investigate its antimicrobial efficiency. By using the 
standardised antimicrobial assay (section 3.2.3), an undiluted 18h culture (stationary 
phase) of each pathogen was treated with an equal volume of undiluted and 
non-pH-adjusted MRSg (harvested at designated time points of secondary fermentation) 
in BHI broth, in triplicate, at 37°C. At predetermined time intervals, aliquots were 
removed, serially diluted, and plated (drop-plating) on BHI agar. Each original 18h 
pathogen culture was enumerated before treatment, and the number of viable cells was 
compared with those in MRSg-treated cultures. A survival rate of each treated pathogen 
was calculated and presented in a graph.  
3.2.7 Viability of DPC16 resting cells in glycerol-fermenting cultures 
The DPC16 resting cells from fresh incubated culture, freeze-drying preparation, and 
the kinetic production of MRSg and SGF were tested for viability. As mentioned in 
Section 3.2.2, resting cell suspensions were sampled at various time points during the 
glycerol fermentation in both glycerol-MRS and glycerol-water, where supernatants of 
MRSg and SGF were obtained. From the same suspensions, the cell pellets were 
harvested, washed and resuspended in PBS, and then diluted and enumerated by 
drop-plate, in quadruplicate, on pre-reduced MRS agar plates. Freshly harvested and 
washed DPC16 resting cells from the 20h culture without glycerol, and those were 
processed with starvation and freeze-drying were also subjected to the above procedure. 
Hence, the viability of DPC16 resting cell from pre-production, preparation process and 
post-production were compared.  
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3.2.8 Statistical analysis 
Statistical analysis for determination of significant differences in the measured 
properties between groups was accomplished using a paired-sample T-test performed 
with 95% confidence intervals. The statistical analysis was done using a statistical 
program (SPSS, v.15, SPSS Inc.; Chicago, Illinois, USA). All data were presented as a 
mean value of replicates (generally n=3, but occasionally n>3) with the standard error 
of the mean (SEM) indicated. This statistical analysis method was used throughout the 
thesis. 
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3.3 Results 
3.3.1 The pH values of DPC16 cell-free supernatants 
The pH values of MRSc and the aqueous solution of freeze-dried MRSc (FZMRSc) 
were measured as 4.4 and 4.2, respectively. The pH values of MRSg and SGF measured 
during their production from glycerol in secondary fermentation are displayed in Figure 
3.1, and show that production of MRSg was accompanied by a continuous decline of 
pH until 16h of incubation, after which the pH value stabilised at pH 4.6. The pH value 
of SGF decreased then slightly rose during incubation, finally reaching a value of 5.2. 
However, it was found that SGF had very low buffering strength, so the pH adjustment 
of this particular supernatant was not carried out and the antimicrobial activity of SGF 
was tested without pH adjustment. Hence, all DPC16 supernatants obtained were acidic, 
where MRSc and FZMRSc produced in primary fermentation had slightly lower pH 
values than MRSg or SGF from secondary fermentation with glycerol. At the end of the 
incubation, MRSg had a lower pH value than SGF and took longer to reach the final 
value. 
 
 
 
 
 
Figure 3.1  The pH values of MRSg and SGF measured during secondary fermentation with 
glycerol. Data points are the mean of triplicate pH values, with SEMs represented as vertical bars. 
 
3.3.2 Primary antimicrobial assay against selected pathogens 
The antimicrobial activities exhibited by different cell-free supernatants of L. reuteri 
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Figure 3.2 shows the inhibition of pathogens treated with MRSc and FZMRSc, with and 
without pH adjustment, in comparison with untreated controls. It is found that only the 
unadjusted supernatants of MRSc and FZMRSc had significant inhibitory effects 
(P<0.05 or P<0.01) against pathogens, whereas their pH-adjusted counterparts did not 
show any significant antimicrobial activity in comparison to the untreated controls. The 
Gram-negative pathogens (S. Typhimurium and E. coli) were more sensitive to MRSc or 
FZMRSc than the Gram-positive pathogens (L. monocytogenes and S. aureus) in terms 
of percentage of inhibition relative to untreated controls. Furthermore, the inhibition by 
FZMRSc was a little higher than that of the MRSc, but the difference did not reach a 
significant level. This also indicates that the freeze-drying process did not have a 
significant impact on the antimicrobial activity of the MRSc supernatant (statistics data 
are presented in Appendix 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2  Primary antimicrobial tests of MRSc and FZMRSc, and their pH adjusted 
counterparts. A, growth of pathogens with or without treatment of original MRSc and FZMRSc; B, 
growth of pathogens with and without treatment of pH-adjusted MRSc and FZMRSc (MRSc-pH 
and FZMRSc-pH); C: Percentage of inhibition of each pathogen as shown in A; D: Percentage of 
inhibition of each pathogen as shown in B. Bar values are presented as means calculated from 
triplicate OD620 readings with SEM shown by vertical bars (n=3). Percentage of inhibition was 
calculated by comparing OD620 of treated pathogens with untreated controls. Pathogen growth is 
significantly inhibited when symbol * P <0.05 or ** P <0.01 is presented.   
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Figure 3.3 illustrates percentage inhibition of growth of each pathogen by original 
MRSg (non-pH-adjusted) harvested during the 20h secondary fermentation with 
glycerol. It is clear that antimicrobial activity of MRSg, against all selected pathogens, 
increased with time of incubation, and a sudden jump was observed between 6h-8h 
(except for S. aureus, where a similar increase occurred sooner during incubation), 
which raised the inhibition percentage to a level of 100%. Table 3.2 shows an example 
of statistical analysis on antimicrobial activity of MRSg (at certain points of incubation) 
against target pathogens, by comparing growth of treated-pathogens with untreated 
controls as well as commercial antibiotics. It suggests that MRSg exerted significant 
inhibition against all pathogens from 2h of incubation, and by 8h of incubation the 
antimicrobial effect of MRSg has no significant difference from the antibiotics. Hence, 
during the production of MRSg, 6h can be considered as a threshold in terms of its 
antimicrobial efficacy against target pathogens (4h in case of S. aureus), where before 
this threshold MRSg exerts its antimicrobial activity similar to MRSc or FZMRSc, and 
beyond this threshold nearly 100% inhibition of all tested pathogens were observed 
similar to antibiotic. 
Table 3.2  Antimicrobial activity of the MRSg (non-pH-adjusted), from selected time points during 
incubation, against target pathogens. Percentage of inhibition and P values are calculated from 
OD620 of treated pathogens comparing to untreated controls (upper panel), or comparing to 
commercial antibiotics (lower panel). Data are means of multiple replicates (n=6), with P<0.05 
indicating significance.  
Antimicrobial Activity  
Growth inhibition 1h P-value 2h P-value 
S. Typhimurium 20.0% ± 0.7% 0.0003 23.3% ± 0.9% 0.0004  
E. coli 8.2% ± 1.7% 0.0878 13.7% ± 1.9% 0.0334  
S. aureus 12.0% ± 0.6% 0.0006 23.1% ± 1.4% 0.0010  
L. monocytogenes 0.5% ± 0.4% 0.6633 5.6% ± 0.5% 0.0070  
Antibiotics Analogue 
Growth inhibition 8h P-value 10h P-value 
S. Typhimurium 99.4% ± 0.1% 1.00 99.6% ± 0.1% 0.16 
E. coli 99.2% ± 0.1% 0.18 99.0% ± 0.1% 0.26 
S. aureus 98.0% ± 0.4% 0.31 99.4% ± 0.1% 0.14 
L. monocytogenes 99.4% ± 0.1% 0.26 99.5% ± 0.0% 0.09 
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A post-treatment viability test was used to count viable pathogen cells after incubation 
with MRSg collected at various time points during the glycerol incubation. Figure 3.4 
shows a sharp decrease in numbers of viable cells after MRSg treatments, especially for 
S. aureus where no viable cells were found after treatment with MRSg harvested after 
8h of secondary fermentation. In the viable counts of 10h MRSg-treated pathogen 
cultures, no viable pathogen cell was detected in any cultures. These results agree well 
with those of the antimicrobial assay in that the antimicrobial activity of MRSg has 
largely increased between 6-8h of secondary fermentation and stabilised thereafter. Also, 
it confirms that S. aureus was the most susceptible to MRSg; and suggests that this 
potent effect of MRSg is bactericidal in nature.  
The pH-adjusted MRSg-8h and its unadjusted form were also tested in an antimicrobial 
assay against the above pathogens. Statistical analysis showed that pH adjustment did 
not make any significant difference to the antimicrobial activity of MRSg-8h against 
any target pathogen (statistics data are shown in Appendix 2). Hence, the inhibitory 
effect of MRSg was pH-independent, effective across a pH range of 4.6 to 6.5, and 
impacted on both Gram-negative and Gram-positive pathogens.  
Figure 3.5 shows % inhibition of pathogens treated with SGF (non-pH adjusted) 
sampled during the 8 h incubation. Unlike the pattern of MRSg, the kinetic series of 
SGF showed very limited antimicrobial activity, and it was only, at a transient moment, 
effective against S. typhi and S. aureus, where a statistic analysis showed that 2 h SGF 
had the highest inhibition against both (P = 0.007 and 0.002, respectively) comparing to 
the untreated controls.  
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Figure 3.3  Primary antimicrobial test of MRSg harvested during secondary fermentation. Values 
are expressed as percentage of inhibition relative to controls, calculated from mean OD620 of 
MRSg-treated pathogens and untreated controls, with SEMs represented by vertical bars (n=3). 
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Figure 3.4  Post-treatment viability test of pathogens treated with MRSg harvested from selected 
time points during secondary fermentation with glycerol. 
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Figure 3.5  Primary antimicrobial test of SGF harvested during secondary fermentation. Values 
are mean percentage of inhibition relative to controls, calculated from OD620 of treated pathogens 
comparing to untreated controls, with standard errors represented by vertical bars (n=3). 
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3.3.3 Dose response test 
From the primary antimicrobial test, DPC16 cell-free supernatants with significant 
inhibitory effects against pathogens were selected for a dose response assay. These 
included the original (pH-unadjusted) MRSc, FZMRSc and MRSg harvested at 8h of 
the secondary fermentation, denoted as MRSg-8h. SGF from a 2h incubated 
glycerol-water culture (SGF-2h) was also selected but only assayed against S. 
Typhimurium and S. aureus for dose response. By comparing the growth of pathogens 
treated by selected DPC16 supernatants with their corresponding untreated controls, a 
series of inhibition bar charts were developed to reveal dose responses of each selected 
cell-free supernatant against target pathogens.  
Figure 3.6 displays the dose-response of MRSc dilutions and the decreasing 
antimicrobial activities against selected pathogens. It is evident that the inhibitory 
effects of MRSc against both the Gram-negative and the Gram-positive pathogens are 
dose dependent, and the antimicrobial activity declines along the binary dilution. 
Statistical analysis shows that significant inhibitions of MRSc against E. coli (P=0.01) 
and S. Typhimurium (P=0.049) were detected at dilutions as far as 80- and 160-fold, 
respectively. However, the minimum effective dose of MRSc against S. aureus (P=0.001) 
and L. monocytogenes (P=0.006) were higher at the 10-fold and 20-fold dilutions of 
MRSc, respectively. This suggests that Gram-negative pathogens are more susceptible 
to acidic MRSc than the Gram-positive pathogens.  
A similar trend of dose response was observed using FZMRSc against the same 
pathogens (Figure 3.7). It was also noted that, at the initial dose (10-fold dilution), the 
FZMRSc had higher inhibitory capability against all pathogens than had MRSc, which 
agrees with the result of the primary tests. But, the minimum effective doses of both 
MRSc and FZMRSc are similar.  
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Figure 3.6  Dose response of original MRSc against pathogens. Values are expressed as percentage 
of inhibition relative to controls, calculated from mean OD620 of MRSc-treated pathogens and 
untreated controls, with SEMs represented by vertical bars (n=3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. Typhimurium
0%
10%
20%
30%
40%
50%
10 20 40 80 160 320 640 1280 2560 5120
MRSc Dilution (fold)
In
hi
bi
tio
n 
( %
  c
on
tro
l )
E.coli O157:H7
0%
10%
20%
30%
40%
50%
10 20 40 80 160 320 640 1280 2560 5120
MRSc Dilution (fold)
In
hi
bi
tio
n 
( %
  c
on
tro
l )
S .aureus
0%
10%
20%
30%
40%
50%
10 20 40 80 160 320 640 1280 2560 5120
MRSc Dilution (fold)
In
hi
bi
tio
n 
( %
  c
on
tro
l )
L. monocytogenes
0%
10%
20%
30%
40%
50%
10 20 40 80 160 320 640 1280 2560 5120
MRSc Dilution (fold)
In
hi
bi
tio
n 
( %
  c
on
tro
l )
Chapter 3         Antimicrobial activity of L. reuteri DPC16 cell-free supernatants 
 41 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7  Dose response of original FZMRSc against pathogens. Values are expressed as 
percentage of inhibition relative to controls, calculated from mean OD620 of FZMRSc-treated 
pathogens and untreated controls, with SEMs represented by vertical bars (n=3). 
Figure 3.8 demonstrates the dose response for the antimicrobial activity of the original 
MRSg-8h. It is observed that the antimicrobial activity of MRSg is dose dependent 
against all assayed pathogens regardless of whether Gram-negative or Gram-positive, 
and more importantly the dose response patterns were almost identical across pathogens 
(except for a little difference with L. monocytogenes at lower doses). The results show 
that the first few dilutions retained the strong inhibitory effect against every pathogen. 
The minimum effective dose of MRSg-8h were at 320-fold dilution for both S. 
Typhimurium and E. coli (p= 0.01 and 0.039, respectively). MRSg treatment continued 
to completely suppress the growth of S. aureus until it was diluted up to 160-fold, and 
the minimum effective dose was determined as the 640-fold dilution (P=0.028). For L. 
monocytogenes, significant inhibition was continued until the minimum effective dose 
of the 640-fold dilution (P=0.0153). SGF-2h, however, did not show any significant 
dose response in its antimicrobial activity against S. Typhimurium or S. aureus (Figure 
3.9). 
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Figure 3.8  Dose response of original MRSg-8h against pathogens. Values are expressed as 
percentage of inhibition relative to controls, calculated from mean OD620 of MRSg-8h-treated 
pathogens and untreated controls, with SEMs represented by vertical bars (n=3). 
 
 
 
 
 
 
Figure 3.9  Dose response of SGF-2h against pathogens. Values are expressed as percentage of 
inhibition relative to controls, calculated from mean OD620 of SGF-2h-treated pathogens and 
untreated controls, with SEMs represented by vertical bars (n=3). 
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From the dose response assays, it is possible to determine the lowest effective dose of 
each selected cell-free supernatant, which still significantly inhibits the growth of target 
pathogens (Table 3.3). 
Table 3.3  The lowest effective dose of each selected original supernatant (non-pH adjusted) 
against target pathogens. 
Dose (fold)  S. Typhimurium E. coli  S. aureus L. monocytogenes 
MRSc 160 80 10 10 
FZMRSc 80 160 20 20 
MRSg (8h) 320 320 640 640 
SGF (2h) 1 - 1 - 
3.3.4 A time course investigation of DPC16 antimicrobial activity on pathogen 
growth  
The purpose of this time course experiment was to investigate the inhibitory effect of 
DPC16 cell-free supernatants on pathogen growth from the following three aspects: the 
length of the lag phase, the growth rate during exponential phase, and the total number 
of pathogen cells at the endpoint of incubation.  
Figures 3.10 to 3.13 show the growth curves of the selected pathogens with and without 
treatments of selected DPC16 supernatant at their minimum effective dose as 
determined previously. Firstly, pathogens treated with the original (pH unadjusted) 
MRSc (Figure 3.10) and FZMRSc (Figure 3.11) had similar patterns of growth with no 
effect on the length of the lag phase. SGF treatment (Figure 3.13) had no significant 
effect on the growth of S. Typhimurium or S. aureus, at all. However, the MRSg-8h 
(Figure 3.12) apparently extended the lag phase of all pathogens from 3h to 6h. Since 
pathogen growth continued, the MRSg, at the dilution used, did not exhibit bactericidal 
activity, but rather might have introduced impaired division or suppression to growth.  
 
 
 
 
Chapter 3         Antimicrobial activity of L. reuteri DPC16 cell-free supernatants 
 44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10  A time course of original MRSc treatment, in minimum effective dose, against 
selected pathogens. Data points are means of triplicate OD620 readings measured along a series of 
time intervals during incubation, with SEMs represented as vertical bars. Drop-down bars between 
growth curves indicated growth differences of MRSc-treated pathogen compared with untreated 
controls.  
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Figure 3.11  A time course of original FZMRS treatment, in minimum effective dose, against 
selected pathogens. Data points are means of triplicate OD620 readings measured along a series of 
time intervals during incubation, with SEMs represented as vertical bars. Drop-down bars between 
growth curves indicated growth differences of FZMRSc-treated pathogen compared with untreated 
controls. 
E.coli O157:H7
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 3 6 9 12 15 18 21
Time (h)
O
pt
ic
al
 D
en
sit
y 
A6
20
nm
FZMRSc
Control
S. Typhymurium
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 3 6 9 12 15 18 21
Time (h)
O
pt
ic
al
 D
en
sit
y 
A6
20
nm
FZMRSc
Control
S. aureus
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 3 6 9 12 15 18 21
Time (h)
O
pt
ic
al
 D
en
sit
y 
A6
20
nm
FZMRSc
Control
L. monocytogenes
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0 3 6 9 12 15 18 21
Time (h)
O
pt
ic
al
 D
en
sit
y 
A6
20
nm
FZMRSc
Control
Chapter 3         Antimicrobial activity of L. reuteri DPC16 cell-free supernatants 
 46 
 
 
 
 
 
 
 
 
 
 
Figure 3.12  A time course of MRSg treatment, in minimum effective dose, against selected 
pathogens. Data points are means of triplicate OD620 readings measured along a series of time 
intervals during incubation, with SEMs represented as vertical bars. Drop-down bars between 
growth curves indicated growth differences of MRSg-treated pathogen compared with untreated 
controls. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.13  A time course of undiluted SGF treatment against S. Typhimurium and S. aureus. 
Data points are means of triplicate OD620 readings measured along a series of time intervals during 
incubation, with SEMs represented as vertical bars. Drop-down bars between growth curves 
indicated growth differences of SGF-treated pathogen compared with untreated controls. 
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The pathogens’ growth rates were calculated, based on the development of optical 
density (OD620) in the exponential phase (6h), as: 
Growth rate
12
12
tt
ODOD
−
−
= . 
The growth rate was determined and compared for each pathogen culture with and 
without the treatments of DPC16 supernatants. Table 3.4 summarises the pathogen 
growth rate with treatment of designated DPC16 supernatants; and the statistical 
significances of DPC16 supernatants affecting the growth rates in comparison with the 
untreated controls were indicated. It is clear that the MRSc and FZMRSc from 
non-glycerol incubation significantly lowered the pathogens’ growth rate (except for E. 
coli O157:H7, this could be due to experimental error since the OD620 data deviated 
greater than the others), whereas the less acidic MRSg from glycerol incubation did not 
have significant effect on the growth rate of pathogens (except for L. monocytogenes). 
SGF did not affect the target pathogens’ growth rate.  
Table 3.4  A statistical analysis of pathogen growth rate with and without treatments from the 
designated DPC16 supernatants. Panel A, pathogen growth rate with MRSc and FZMRSc 
treatment; panel B, pathogen growth rate with MRSg and SGF treatment. The growth rates were 
calculated from triplicate OD620 readings at the beginning and end point of the exponential phase, 
and by comparing with those in untreated control, a paired sample T-test was performed and P 
values were presented, where P <0.05 indicating significance.  
A.  
Growth Rate (h-1) control MRSc P value control FZMRSc P value 
S. Typhimurium 0.074 ± 0.002  0.059 ± 0.001  0.015  0.074 ± 0.002  0.060 ± 0.002 0.026  
E. coli 0.073 ± 0.001 0.056 ± 0.003 0.074  0.073 ± 0.001 0.054 ± 0.004  0.085  
S. aureus 0.065 ± 0.001  0.056 ± 0.000 0.011  0.065 ± 0.001 0.053 ± 0.001 0.002  
L. monocytogenes 0.056 ± 0.001 0.047 ± 0.001  0.036  0.056 ± 0.001 0.046 ± 0.002 0.101  
B. 
Growth Rate (h-1) control MRSg P value control SGF P value 
S. Typhimurium 0.053 ± 0.004 0.059 ± 0.001 0.446  0.074 ± 0.002 0.067 ± 0.001 0.071  
E. coli 0.072 ± 0.001 0.062 ± 0.001  0.053  - - - 
S. aureus 0.065 ± 0.001 0.050 ± 0.002 0.121  0.065 ± 0.001  0.058 ± 0.001 0.105  
L. monocytogenes 0.057 ± 0.001 0.047 ± 0.000 0.002  - - - 
Finally, the optical density at the endpoint of incubation, reflecting the total number of 
pathogen cells, was measured and compared with those of the untreated controls. A 
statistical analysis shows that, except for SGF, almost every selected DPC16 
supernatant has significantly decreased the final concentration cells produced during 
pathogen growth (Table 3.5). 
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Hence, at the minimum effective dose, MRSc and FZMRSc inhibited the pathogen 
growth by effectively decreasing the growth rate; while MRSg, a derivative from 
DPC16 glycerol fermentation, exerted its strong antimicrobial activity by elongating the 
lag phase of pathogen growth and significantly reducing the total number of pathogen 
cell in stationary phase. SGF did not show any effective inhibition activity during this 
time course.   
Table 3.5  A statistical analysis comparing the number of total pathogen cells at endpoint of the 
incubation, between pathogens treated with respective DPC16 supernatants and the untreated 
controls.  Data are mean OD620 from triplicate readings, which reflect the cell concentration at the 
end of the incubation. The P values are calculated from a paired sample T-test (n=3), with P<0.05 
indicating significance.  
A. 
OD620 Control MRSc P-value FZMRSc P-value 
S. Typhimurium 0.631 ± 0.007  0.533 ± 0.011  0.027  0.529 ± 0.006  0.004  
E. coli 0.651 ± 0.014 0.529 ± 0.001 0.027  0.510 ± 0.007 0.008  
S. aureus 0.559 ± 0.012 0.447 ± 0.001 0.027  0.480 ± 0.001 0.019  
L. monocytogenes 0.501 ± 0.003 0.421 ± 0.010  0.018  0.433 ± 0.007 0.016  
B.  
OD620 Control MRSg P-value SGF P-value 
S. Typhimurium 0.631 ± 0.007  0.455 ± 0.004 0.005  0.592 ± 0.007  0.110  
E. coli 0.651 ± 0.014 0.478 ± 0.013 0.021  - - 
S. aureus 0.559 ± 0.012 0.410 ± 0.001  0.011  0.596 ± 0.006 0.094  
L. monocytogenes 0.501 ± 0.003 0.388 ± 0.09  0.004  - - 
 
3.3.5 An antimicrobial efficiency test on MRSg 
The strong antimicrobial activity of DPC16 supernatant MRSg was further studied 
using a viable cell count assay to investigate its efficiency in killing pathogen cells. 
Table 3.6 shows the survival rate of pathogen cells when in contact with MRSg-8h for a 
certain period of time. The survival rate was calculated by comparing viable pathogen 
cells enumerated at each time point to that in its original 18h culture counted prior to 
treatment. It is clear that viability of all pathogens decreased with increasing contact 
time with MRSg-8h. The impact on bacterial cells was almost immediate for all 
pathogens. It is interesting to note that S. aureus was the most susceptible, and the 
number of viable cells hugely declined as the contact with MRSg continued, resulting in 
99.9999% (a reduction of 6 log scale) of the cells killed after 180min of treatment. 
Another Gram-positive pathogen, L. monocytogenes, also largely lost its viability during 
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the MRSg treatment, however it had higher survival rate of 0.221% than any other 
tested pathogens. A steady decrease of cell viability was observed in both S. 
Typhimurium and E. coli O157:H7, with survival rate after 180min contact with MRSg 
being 0.014% and 0.001%, respectively.  
Table 3.6  Sensitivity of pathogens to MRSg-8h treatment. Data represent survival rate of 
pathogen cells, calculated by comparing the viable cells in the treated pathogen cultures with the 
untreated cultures, and are presented as mean of triplicates. 
 
3.3.6 Viability of DPC16 resting cells in glycerol-fermenting cultures 
The viability of DPC16 cells from different stages of glycerol-fermentation in both 
MRSg- and SGF-production culture is displayed in Figure 3.14.  
The freeze-drying process used in this study (without supporting medium) had a very 
significant affect (P<0.001) on the cell viability, and resulted in a 72.3% reduction in the 
number of viable cells.  
Decreases in cell viability were observed in both cultures producing MRSg or SGF, but 
cell death pattern were completely different. Both coming from the process, (starving 
and then freeze-drying), the cells producing MRSg lost their viability in a steady 
process, while those in SGF-producing cultures started to die almost immediately after 
inoculation and in at a much faster rate. After 4h of incubation in glycerol-water, the 
number of viable DPC16 cells had dropped by more than 7 log scale. A statistical 
analysis showed that the viability of cells after 6h of producing MRSg was still 
significantly higher than that detected after the first hour incubation in glycerol-water 
(P<0.001), even though the initial viability of cells inoculated pre-incubation was the 
same for both. These results signify that cell death occurred earlier and faster in SGF 
than in MRSg. It is also noted that, during the later incubation (10h-20h) in the 
MRSg-producing culture, the viability of DPC16 cells had significantly decreased, and 
by the end of production (20h), the number of viable cells had dropped more than 4.5 
log scale.  
Contact Time (min) 15 35 50 70 90 120 150 180 
S. Typhimurium 75.2% 59.8% 54.3% 42.9% 15.2% 17.9% 0.3% 0.014% 
E. coli 74.3% 59.7% 62.6% 53.1% 25.3% 14.2% 0.1% 0.001% 
S. aureus 3.3% 0.832% 0.533% 0.121% 0.047% 0.01% 0.004% 0.000% 
L. monocytogenes 78.6% 16.2% 15.1% 7.0% 1.6% 4.0% 1.1% 0.221% 
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Figure 3.14  A time trend of cell viability of L. reuteri DPC16 resting cells in batch culture 
incubation of glycerol supplemented media. Values are mean log CFU/mL with SEMs represented 
by vertical bars (n=4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B-SGF production
0
2
4
6
8
10
12
14
Fresh Freeze-
dried
1hr 2hr 3hr 4hr
Lo
g 
C
FU
 m
L-1
A-MRSg production
0
2
4
6
8
10
12
14
Fresh Freeze-
dried
6hr 8hr 10hr 20hr
Lo
g 
C
FU
 m
L-1
Chapter 3         Antimicrobial activity of L. reuteri DPC16 cell-free supernatants 
 51 
3.4 Discussion 
The objective of this chapter was to evaluate the antimicrobial activities of various 
cell-free supernatants from DPC16 against selected pathogens, in vitro. The tested 
supernatants are described in Table 3.1. 
Prior to antimicrobial assays, the pH measurement of each candidate supernatant 
showed that the MRSc (pH 4.4) and FZMRSc (pH 4.2) from non-glycerol incubation of 
DPC16 in MRS were more acidic than those from incubations with glycerol, which 
indicates that the cells might have taken an alternative metabolic pathway and produced 
less acidic end-products when glycerol is present, as reported by Talarico et al. (1990). 
The pH change in MRSg was a steadily decreasing process, which took a longer time 
and resulted with a much lower pH value at the final stabilised state than in SGF. This 
has suggested that resting cells have undergone more metabolic processes in 
glycerol-MRS than in glycerol-water. The oscillatory behaviour of pH values in SGF 
indicates a process in which few acidic products were produced at the initial stage, but 
such production ceased early and the acids were quickly neutralised leaving the culture 
with a near-neutral pH with a very low buffering strength (due to the low concentration 
of salts).  
The results of a primary antimicrobial assay have shown that MRSc and FZMRSc 
significantly inhibited the growth of all selected pathogens, whereas their pH-adjusted 
counterparts did not show any inhibition. This means the major antimicrobial activity in 
these two supernatants was most likely due to their acidic components. The role of 
SCFA (e.g. lactic acid, acetic acid, formic acid, succinic acid, etc.) produced in probiotic 
Lactobacillus species have been reported to be responsible for strong antimicrobial 
activity against all the pathogens studied in this chapter (Jin et al., 1996; Lehto and 
Salminen, 1997; De Keersmacker et al., 2006; Hutt et al., 2006; Millette et al., 2007). 
The acidic effect of SCFA on the growth of pathogens has been intensively studied and 
the mechanism is believed to be associated with the dissociation of SCFA across 
transmembrane pH-gradient. LAB can produce SCFA and secret them extracellularly, 
hence decrease the pH value of local environment. At relatively low pH, these SCFA 
remain undissociated; and as being lipophilic, undissociated SCFA are able to penetrate 
the bacterial membrane and subsequently dissociate when encountering the relative 
higher intracellular pH, hence resulting in releasing large amounts of free hydrogen ions 
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and generating a large transmembrane proton gradient which interferes with essential 
metabolic functions of affected bacteria (Baird-Parker, 1980; Booth, 1985). The 
pathogens tested in this experiment (S. Typhimurium, E. coli O157:H7, S. aureus, and L. 
monocytogenes) are all neutrophilic bacteria, and they are sensitive to changes of 
extracellular pH values.  
In addition, it is also found that there was no difference between MRSc and FZMRSc in 
their inhibitory effect against selected pathogens, so the freeze-drying process does not 
affect the substances in exerting their antimicrobial activity in solution.  
In addition to MRSc and FZMRSc, the same antimicrobial assay was carried out with a 
kinetic profile (a series of supernatant harvested from designated time points during 
incubation) of MRSg and SGF from glycerol fermentation with two-fold concentrated 
DPC16 resting cells obtained from the stationary phase of a previously incubated 
DPC16 culture. The MRSg series produced by glycerol-MRS fermentation (molar 
concentration ratio of glycerol:glucose = 360:110 mM) has demonstrated a very strong 
antimicrobial activity against all pathogens both before and after the pH-adjustment. 
This inhibitory effect of MRSg developed slowly during the first few hours of 
incubation, but an exponential increase was observed between 6-8h (4-6h for S. aureus) 
of incubation resulting nearly 100% inhibition thereafter. A post-treatment viability 
count of pathogens treated between the ends of the exponential increase confirmed that 
the antimicrobial activity of MRSg has turned from moderate inhibition into complete 
bactericidal. These results suggested that certain antimicrobial-potent substances other 
than SCFA were synthesised and started to exhibit activity during this period of 
incubation. Salameh et al. (2003) reported the observation of total growth inhibition of 
E. coli O157:H7 when treated with supernatant obtained from a variety of strains of L. 
reuteri incubated in glycerol-supplemented MRS. They also reported that this total 
inhibition of pathogen could be observed within 4h of treatment. Interestingly, the result 
of the antimicrobial efficiency test using the MRSg-8h has agreed with this report in 
that the supernatant was able to, almost-totally, inhibit the pathogen growth within 3h 
(180 min) of contact in solution.  
It is also noticed that this strong antimicrobial activity appeared suddenly after a few 
hours of initial incubation, where the antimicrobial activity was similar to that of the 
acidic effect. It is assumed that this is due to either the adaption of DPC16 cells to the 
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environment prior to its subsequent production of a certain potent substance, or the 
existence of a certain tolerance threshold where pathogens can only tolerate certain 
substances in the media to a certain level, and when the amount of such substances 
exceeds this threshold, the pathogen growth is largely inhibited. Also, antimicrobial 
activity of this synthesised substance is strain specific.  
The exact identification of the potent antimicrobial agent(s) produced in MRSg during 
the exponential increase of antimicrobial activity is unknown. However, it (or one of 
them) may be reuterin. Talarico et al. (1990) identified reuterin from glycerol-glucose 
co-fermentation of L. reuteri 1063 by means of HPLC and FTIR, and they claimed that 
L. reuteri could utilise exogenous glycerol as a hydrogen acceptor during carbohydrate 
fermentations, resulting in higher growth rates and cell yields than those obtained 
during growth on carbohydrates alone. According to Axelsson et al. (1989), reuterin, 
from L. reuteri, is a broad spectrum antimicrobial compound. Arques et al. (2004) 
studied the antimicrobial activity of reuterin against different food-borne Gram-positive 
and Gram-negative pathogens in milk, and found that reuterin (8 arbitrary units /mL) 
exhibited bacteriostatic activity against Listeria monocytogenes, whereas bactericidal 
activity was detected against E. coli O157:H7, Salmonella choleraesuis subsp. 
choleraesuis, Yersinia enterocolitica, Aeromonas hydrophila subsp. hydrophila and 
Campylobacter jejuni. Rasch (2002 a) observed an increased inhibitory activity of 
reuterin against E. coli as the temperature was increased within the range of 10-30°C, 
whereas variations in pH (4.5–6.5) and salt content (0.5–3%) did not influence the 
inhibitory activity. The results of pH-independent and strong antimicrobial activity of 
MRSg harvested after 8h of secondary fermentation have been consistent with the above 
findings. 
Although both MRSg and SGF were produced from glycerol fermentation using 
published methods, SGF showed different antimicrobial activity when compared with 
the MRSg. Instead, it only transiently inhibited S.aureus and S. Typhimurium with SGF 
from 2h incubation. This difference in activity is probably due to the difference in the 
composition of the media. In the production of MRSg, the DPC16 resting cells were 
able to continue metabolising while excessive glycerol was supplied. In contrast, the 
same set of resting cells had no fermentable source of carbohydrate, and this might 
result in metabolism ceasing shortly after the start of incubation as seen in the transient 
pH drop, and eventual cell death. This result suggests that this strain of L. reuteri may 
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not be able to utilise glycerol alone. Latest research has reported that the efficacy of 
reuterin production is highly variable amongst different strains of L. reuteri due to 
variations in gene expression of associated enzymes (Spinler et al., 2008).  
With the minimum effective dose of each cell-free supernatant determined in a dose 
response assay, a time course of pathogen growth was carried out to further characterise 
the supernatants’ antimicrobial effect. It was found that treatment with MRSc and 
FZMRSc did not affect the length of lag phase of pathogen growth, but lowered the 
growth rate, and as a result, the total pathogen cell numbers were decreased. This 
indicates that the acidic effect from SCFA could affect the exponential phase of 
pathogen growth by interfering with cell-division resulting in lower cell numbers in the 
stationary phase. However, MRSg, which possibly contained reuterin, acted quite 
differently. By adding the lowest effective dose of MRSg into the pathogen cultures, 
prolonged lag phase was observed for each pathogen. It is assumed that MRSg, at this 
very low concentration (320- to 640-fold), has introduced a stress response to the 
pathogens, so that the cells had to spend more time adapting to the media environment. 
It is interesting to note that only the growth rate of L. monocytogenes was affected by 
MRSg-8h. This may be due to a low level of glycolysis by the resting cells, as seen with 
high pH value (pH 5.1) of MRSg-8h. However, the total cell number of each pathogen 
treated with MRSg-8h was significantly reduced in its stationary phase. Recently, Rasch 
et al. (2007) reported that reuterin elongated the lag phase and induced cell variance to 
Listeria innocua, and at last completely prevented the cell division, irrespective of 
different pH values and NaCl concentrations in the media environment.  
The transient antimicrobial activity of SGF-2h was also tested in the time course against 
its target pathogens with the original undiluted dose. However, no significant 
antimicrobial effect was detected with either the lag phase, the growth rate or the final 
cell numbers of the target pathogens’ growth. The completely different antimicrobial 
activity of SGF from MRSg has pointed to the possibility that there may be no reuterin 
in SGF, and that there is no SCFA produced from normal cell metabolism either, since 
the acidic effect was not seen. 
An efficiency test for the strong antimicrobial activity of MRSg-8h showed that all 
selected pathogens were very susceptible to this supernatant at its undiluted dose, and a 
bactericidal effect was observed with 3h of treatment. This suggests that at relatively 
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high concentration, the MRSg (putatively containing reuterin presence) has bactericidal 
or bacteriolytic effect; while at lower concentration, MRSg suppresses pathogen growth 
by introducing certain stress response to impair and delay pathogen cell replication. The 
reason for such difference was not investigated during this study, but it could possibly 
be attributed to the change of molecular structure of the putative reuterin in an aqueous 
solution. For example, Vollenweider et al. (2003) reported that the distribution of the 
three β-hydroxypropionaldehyde (HPA) compounds forming the reuterin system was 
concentration-dependent in aqueous solution. At high concentrations, reuterin 
predominantly exists in the cyclic dimer form; while at lower concentrations, the 
majority of reuterin is in the hydrated form.  
Finally, a viability test on the DPC16 cells producing MRSg and SGF was conducted. 
The large decrease of cell viability in MRSg-producing cells, observed after the huge 
increase of extracellular antimicrobial activity, has indicated that MRSg is not only 
competent to inhibit the pathogen growth, but also it can exert a significant impact on 
the viability of its own cells. Lethal effect of accumulated reuterin on L. reuteri cells in 
prolonged incubation has been previously reported (Talarico et al., 1988; Chung et al., 
1989; Rasch et al., 2002 b). However, it was also believed that Lactobacillus species, 
including L. reuteri itself, are about 4-5 times less sensitive to reuterin than the 
pathogens (Chung et al., 1989), and this decrease in viability occurs only when the L. 
reuteri cells have been encountered with a very high concentration of reuterin for a long 
duration (Doleyres et al., 2005). In addition, the death of L. reuteri cell was reported to 
be independent of reuterin concentration (Rasch et al., 2002 b). These published 
findings have provided more evidence, from another perspective, of the presence of 
reuterin, since the cell death pattern in MRSg coincided with that described in the above 
reports.  
The cells in SGF-producing culture, however, behaved completely different from those 
producing MRSg, even though they had the same initial viability. The cell death in 
glycerol-water fermentation occurred as soon as the incubation started, and the starved 
cells died very fast in this non-growth medium. This provides evidence to the previous 
explanation that L. reuteri DPC16 cannot metabolise in a solution where only glycerol 
was supplied, hence the starved resting cells died due to lack of nutrients. However, the 
transient inhibitory effect of SGF to the most susceptible S. aureus was observed, and a 
transient pH drop was evidenced. Whether, or not, there is reuterin produced in the 
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glycerol-water fermentation can only be determined with reuterin quantification of the 
SGF kinetic profile. .  
In summary, the L. reuteri DPC16 cell free supernatants MRSc and FZMRSc, harvested 
from MRS broth without glycerol, showed significant inhibitory activity against all 
selected pathogens, and it is thought to be mainly due to the acidic effect of SCFA as 
evidenced by the loss of activity in their pH-adjusted counterparts. This acidic effect 
was shown to reduce the pathogen growth rate and decrease the total pathogen cell 
numbers in a time course study. The kinetic profile of MRSg, obtained during 
incubation of DPC16 resting cells in glycerol-supplemented MRS broth has shown very 
strong antimicrobial activity against all target pathogens. This antimicrobial activity is 
pH-independent, and impacted on both Gram-negative and Gram-positive pathogens. It 
is assumed that reuterin may be present in MRSg. By comparing the antimicrobial 
activity of MRSg in high and low doses, it was found that MRSg, at a high dose, had a 
potent bactericidal effect resulting in pathogen cell death within 3h of treatment, while, 
at a low dose, MRSg was bacteriostatic by inducing a stress response to pathogen cells 
during lag phase and hence delaying cell replication. However, this strong antimicrobial 
activity can also act on DPC16 itself by significantly reducing its cell viability. But, this 
self-inhibiting activity occurred moderately and was tolerable until late in the 
fermentation. SGF, another glycerol fermentation product tested in this study, did not 
show a clear antimicrobial activity, did not develop a normal acidic cultural pH, and the 
cells producing SGF died very quickly. These suggest that there was no normal cell 
metabolism by the DPC16 cells in glycerol-water, and this strain may not be capable of 
producing reuterin without the presence of fermentable carbohydrate.  
The interesting findings of the strong antimicrobial activity of MRSg has led to 
additional studies in the next chapter, where the growth kinetics of DPC16 (e.g. growth 
rate and biomass) were studied, reuterin productivity was measured, the relationship 
between reuterin concentration and the antimicrobial activity of MRSg was obtained, 
and the DPC16 cell viability during reuterin production was examined.  
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Chapter 4 
Kinetics of Lactobacillus reuteri DPC16 growth and in situ reuterin 
production in a two-step fermentation process 
4.1 Introduction 
Lactobacillus reuteri is a Gram-positive lactic acid bacterium belonging to the obligate 
heterofermentative group, which preferentially uses the phosphoketolase pathway for 
metabolism. It resides as a major component of enterolactobacilli in the GI tract of 
various hosts ranging from birds to humans, where it establishes a symbiotic 
relationship (Casas and Dobrogosz, 2000). Anaerobic resting cells of this species can 
convert glycerol into a broad-spectrum antimicrobial substance of 3-hydroxy- 
propionaldehyde, termed reuterin (Chung et al., 1989). Reuterin, from L. reuteri, is 
synthesised intracellularly as an intermediate product from glycerol by a 
cobalamin-dependent enzyme, glycerol dehydratase. Some of the reuterin is further 
reduced to 1,3-propanediol by an NAD-dependent oxidoreductase (Talarico et al., 1990; 
Luthi-Peng et al., 2002 a), while the rest is accumulated and subsequently excreted to 
extracellular environment under normal physiological conditions of temperature and pH 
(Talarico et al., 1988). A common practical method to measure reuterin is a colorimetric 
assay introduced by Circle et al. (1945) to measure acrolein, which is a dehydration 
derivative of reuterin produced in equimolar concentrations to reuterin in a heated acid 
aqueous solution. This method has been widely used for detection and quantitative 
determination of reuterin; is simple to conduct and delivers accurate results (Slininger et 
al., 1983; Talarico et al., 1990; Luthi-Peng et al., 2002 a, 2002 b; Vollenweider and 
Lacroix, 2004).  
Several approaches have been made to characterise the growth kinetics of L. reuteri. A 
mathematical model consisting of four coupled differential equations has been 
developed to predict concentrations of biomass, glucose and glycerol as well as reuterin 
production with time, in a batch culture fermentation of L. reuteri (Rasch et al., 2002 b). 
Another batch fermentation model was recently established (Tobajas et al., 2007) to 
describe the production kinetics (biomass concentration, utilisation of glycerol substrate, 
reuterin and 1,3-propanedial production) by using starved L. reuteri PRO137 resting 
cells in a two-step process under controlled conditions.  
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Experiments in this chapter were conducted with the aim of understanding the growth of 
L. reuteri DPC16 in terms of specific growth rate, biomass production and reuterin 
productivity under standardised growth conditions. Attempts were made to confirm the 
existence of reuterin in culture supernatants (MRSg and SGF as prepared in Chapter 3), 
as well as to establish a correlation between reuterin and its corresponding antimicrobial 
activity specified in quantitative terms.   
Chapter 4                    Kinetics of DPC16 growth and reuterin production 
 59 
4.2 Materials and Methods 
4.2.1 Culture preparation  
Cultivation of DPC16 followed the method introduced in Section 3.2.2, and a 20h 
culture was prepared in pre-reduced MRS and subsequently enumerated on MRS agar 
plate using the drop-plate method. The culture was then binary diluted with peptone 
water up to 32-fold, and the turbidity of each dilution reflected by optical density 
(OD620) was measured, in triplicate, using a spectrophotometer (MK3, Genova, Jenway; 
UK). Thus, a correlation curve of OD620 and viable cell counts (CFU/mL) was 
established. The pH value of the 20h DPC16 culture was also measured using a pH 
meter (Orion, Thermal Scientific, USA) at room temperature.  
4.2.2 Growth curve of L. reuteri DPC16 in pre-reduced MRS broth 
Based on the number of viable cells in the 20h culture, a dilution containing 
approximate 104 CFU/mL of DPC16 cells was prepared as a subculture inoculum 
capable of producing a full growth curve with defined length of lag phase. Then, the 
growth curve was developed over a time course experiment by monitoring the changes 
of OD620 during the subculture incubation. Briefly, 1% (v/v) of the DPC16 subculture 
inoculum (104 CFU/mL) was aseptically transferred into a pre-reduced MRS broth, and 
incubated anaerobically at 37°C for up to 20h. During the incubation, the OD620 value 
was measured, in triplicate, at 2h time intervals, and the growth curve was plotted with 
the mean OD620 value collected at each time point against incubation time. The growth 
of DPC16 under the above standardised conditions was characterised by the length of 
lag phase, slope of the exponential phase (based on optical density), and the total viable 
cells at the endpoint of incubation (stationary phase).  
4.2.3 Measurement of DPC16 dry matter by freeze-drying  
At the end of the above incubation, the culture was centrifuged and the concentrations 
of dry materials were measured by freeze-drying. Following the same process as 
described in Section 3.2.3, total biomass (dry cells) and lyophilized culture supernatant 
of this DPC16 culture were measured, in quadruplicate. A correlation curve between 
OD620 and cell dry weight (CDW) was developed using the same culture. Briefly, the 
culture was binary diluted up to 8-fold, and each dilution was measured for OD620 value, 
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and then centrifuged at 4,000 x g for 10 min at 4°C in pre-weighed centrifuge tubes. The 
supernatants were discarded; and the cell pellets were washed twice with PBS, 
centrifuged again and finally freeze-dried for 48h. Hence, the total CDW for each 
dilution was measured, and the relationship between culture OD620 and CDW was 
obtained.  
4.2.4 Colorimetric determination of glycerol and reuterin  
The DPC16 cell-free supernatants of MRSg and SGF, in their kinetic profiles, produced 
from glycerol fermentation as introduced in Chapter 3, were quantitatively analysed for 
their glycerol residue and reuterin content after the assays of their antimicrobial activity. 
The determinations of glycerol and reuterin are described as below.   
4.2.4.1 Glycerol 
The colorimetric method of Spagnolo (1953) was used with some modifications. It was 
based upon the formation of blue colour developed by the cupric-glycerol complex in 
basic solution. Briefly, a series of glycerol standards were firstly prepared, in duplicate, 
with 0-20 mg/mL (0-217.4 mM) of stock glycerol (95% analytical grade, LabServe, 
Biolab, New Zealand) in 10 mL distilled water. An aliquot of each standard (1 mL) was 
subsequently added into a mixture containing 1 mL of 20% sodium hydroxide and 6.0 
mL of 95% (v/v) ethanol. Then, with vigorous swirling, a volume of 0.6 mL of 10% 
cupric chloride was added slowly into the above mixture. This mixture was finally 
diluted to a 10 mL volume with 95% ethanol. These standard solutions were 
vortex-mixed vigorously for 2 min, and the well-mixed solutions were centrifuged at 
420 x g for 5 min. The clear supernatants were collected and transferred into matched 
spectrophotometer cuvettes to measure the absorbance at 635 nm against a reagent 
control (similarly prepared using 1 mL of water in place of the glycerol standard). Thus, 
a standard curve of glycerol in aqueous solution was produced spectrophotometrically. 
Details on preparation of the glycerol standards are shown in the Appendix 3. 
The original MRSg and SGF were firstly neutralised to pH 7 using 0.1 M NaOH. Then, 
an aliquot of each neutralised supernatant (0.5 mL) was diluted with an equal volume of 
distilled water to bring the possible glycerol residue concentration within the detectable 
range of the standard curve prepared above. Subsequently, aliquots of each diluted 
supernatant (1 mL) were subjected to the above procedure to measure colour formation, 
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and the glycerol content in each supernatant was determined by interpolation within the 
glycerol standard curve, in duplicate. A medium control replacing DPC16 supernatants 
with respective glycerol-supplemented medium (glycerol-MRS or glycerol-water) was 
also prepared for each supernatant.  
4.2.4.2 Reuterin 
The colorimetric assay for reuterin followed the acrolein method of Circle et al. (1945) 
with some modifications. Stock acrolein solution (BioChemika, Fluka, Sigma; EU) was 
provided by Crop and Food Research, New Zealand. Prior to test, stock acrolein was 
1000-fold diluted with 95% ethanol, and this dilution was used for preparation of an 
acrolein standard. Acrolein standards, containing 0-120 µg/mL in 10 mL final volume, 
were firstly prepared in 95% ethanol (2mL each). A tryptophan solution was made up to 
0.01 M by dissolving crystalline DL-tryptophan (Sigma, USA) in 0.05 M HCl, and 0.5 
mL of the tryptophan solution was added to each acrolein standard. Subsequently, 6.3 
mL of 12 M HCl (37%, J. T. Baker Chemical Co.; USA) was added to each acrolein 
standard. Lastly, an additional 1.2 mL of 95% ethanol was added to each standard 
mixture to make up to the total volume of 10 mL. All standards were prepared in an ice 
bath to prevent premature heating. Once prepared, the standards were transferred 
immediately into a 40°C water bath, and incubated for 50 min to reach the maximum 
colour development. After incubation, all standards were placed immediately back to 
the ice bath to stabilize the colours, and subsequently measured for absorbance at 560 
nm in matched spectrophotometer cuvettes. A reagent control containing 2 mL of 
ethanol replacing the acrolein standard was used for adjustment of the 
spectrophotometer. Details on preparation of the acrolein standard are shown in the 
Appendix 3. 
Original DPC16 supernatants of MRSg and SGF were diluted 2000- and 1000-fold, 
respectively, with 95% ethanol. An aliquot of each diluted supernatant (1 mL) was then 
mixed with 95% ethanol (1 mL) and subjected to the same procedure as above. Acrolein 
concentrations were measured in triplicate, and the molar equivalent of reuterin 
kinetically produced in each DCP16 glycerol-fermentation culture was then determined.  
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4.2.5 Relationship between reuterin and the antimicrobial activity in DPC16 
supernatants from glycerol fermentation  
Having measured the reuterin concentration in both MRSg and SGF profile, the 
synthesis profile of reuterin was compared with the degree of antimicrobial activity in 
each supernatant from glycerol fermentation as determined in Section 3.3.2, and hence a 
relationship between reuterin and cultural antimicrobial activity was established.   
 
4.3 Results 
4.3.1 Viable cell enumeration and pH measurement of DPC16 culture 
Enumeration showed that the population density of the DPC16 culture, after 20h 
incubation in reduced MRS broth, reached 9.62 ± 0.01 log CFU/mL (4.23 x 
109 CFU/mL). The culture pH value was 4.44 ± 0.03. A correlation curve of OD620
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concentration of viable cells in the above DPC16 culture was displayed in Figure 4.1, 
and this was used to predict the concentration of viable DPC16cells in culture.  
 
Figure 4.1  Correlation curve of OD620 and the numbers of viable cells, expressed in CFU/mL, in a 
DPC16 culture incubated in MRS for 20h. Data points are means of triplicate measurements in 
both scales, with SEMs represented as vertical or horizontal bars for CFU/mL or OD620, 
respectively. The mathematical equation with a fitting coefficient R2 indicates the correlation.  
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4.3.2 Growth of L. reuteri DPC16 in MRS under anaerobic condition 
Using diluted subculture inoculum (104 CFU/mL) as a starter culture, a growth curve of 
L. reuteri DPC16 was developed (Figure 4.2). It shows a lag phase of 8h while slight 
growth was observed at 10h with exponential growth occurring thereafter, until 14-16h 
where the growth slowed down and the stationary phase was approached. By plotting a 
regression line within the clearly linear range of the exponential phase, a slope of 0.137 
h-1 was determined and subsequently used to calculate the specific growth rate.  
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Figure 4.2  Growth curve of DPC16 in pre-reduced MRS during anaerobic incubation at 37°C. 
Data points are means of triplicate OD620 readings, with SEMs represented as vertical bars. A 
regression line linearly fitting the exponential phase of growth was also plotted, with a 
mathematical equation indicating the slope.  
Dry materials including separated dry cells and lyophilised cell-free supernatant of 
DPC16 after 20h of incubation were obtained by freeze-drying. The concentration of 
biomass was 5.5 ± 0.7 g/L and lyophilized cell-free supernatant was 49.6 ± 1.4 g/L, 
which contributed to the total dry matter of 55.1 ± 1.5 g/L. It was noticed that a slight 
loss of mass balance occurred during the processes (incubation and subsequent 
freeze-drying) as the total ingredients input was 55 g/L (comparing the 49.6 g/L of dried 
supernatant with the 55 g/L of raw material of MRS broth, and excluding weight of 
bacteria cells). Thus, 5.5 g/L of dry resting cells of DPC16 corresponded to 4.23 x 109 
CFU/mL, and in the secondary fermentation process for glycerol conversion to reuterin, 
the two-fold concentrated biomass was about 11 g/L.  
A similar freeze-drying process on a dilution series of the same culture has produced a 
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correlation curve of cell dry weight (CDW) to cultural optical density (OD620). As 
shown in Figure 4.3, the OD620 and CDW of the 20h DPC16 culture had a linear 
relationship, so it can be used to predict CDW based on culture turbidity.  
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Figure 4.3  Correlation curve of OD620 and CDW of DPC16 culture incubated in MRS for 20h. 
Data points are means of triplicate measurements in both scales, with SEMs represented as vertical 
or horizontal bars for CDW or OD620, respectively. The mathematical equation with a fitting 
coefficient R2 indicates the linear correlation. 
By incorporating this relationship into the growth curve observed in the 20h DPC16 
culture (Figure 4.2), the optical density values in the linear range of the exponential 
phase were translated into CDW, so that the specific growth rate (h-1) was calculated as 
follow: 
=
−
−
=
12
12
tt
LnCDWtLnCDWtµ  0.6 h-1. 
The population doubling time (Td) was accordingly determined using the following 
equation: 
Td=
µ
2
12
2)12( Ln
LnCDWtLnCDWt
Lntt =
−
×− =1.16h. 
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4.3.3 Bioconversion of glycerol and yield of reuterin from biomass 
The production kinetics of bioconversion of glycerol into reuterin in DPC16 
glycerol-MRS fermentation is shown in Figure 4.4. A steady increase in glycerol 
utilisation was accompanied by a sigmoidal increase of reuterin, and the reuterin 
production increased markedly between 6h to 8h of the secondary fermentation and 
levelled after 10h. In SGF, however, even though a slight decrease in glycerol 
concentration was observed, the detectable reuterin was negligible [(no visible colour 
development and OD620 data were not detectable over the reliable range (OD<0.1)] thus 
it is assumed that glycerol bioconversion did not occur in glycerol-water fermentation 
and no reuterin was produced. The glycerol utilisation in SGF was considered as being 
absorbed into DPC16 resting cells and saturation was reached after 2h of incubation 
with average intracellular glycerol concentration of 10.4 mM.  
 
 
 
 
 
 
 
 
Figure 4.4  Time course of L. reuteri DPC16 resting cells bioconversion of glycerol to reuterin in 
MRSg (A) and SGF (B). A: concentrations of utilized glycerol relative to medium control (■) and 
reuterin production (♦) detected in MRSg kinetic profile; B, glycerol utilisation relative to medium 
control detected in SGF kinetic profile. The data points represent means of duplicate OD635 
measurements for glycerol in A and B, and triplicate OD560 measurements for reuterin in A. SEMs 
are represented as vertical bars.  
Based on the above assumption, an actual glycerol utilisation of 85.8 mM was 
calculated in glycerol-MRS fermentation while producing MRSg, resulting in 23.8% 
utilisation of the total glycerol supplementation (360mM). At the end of the 18h 
fermentation (MRSg profile was tested for reuterin up to 18h), there was 62.5 mM 
(calculated as an average concentration from 12h to 18h) of reuterin detected in the 
culture supernatant, and hence the yield of reuterin from utilised glycerol was 72.8%.  
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From the reuterin concentration detected in MRSg profile, another kinetic parameter of 
reuterin production rate was obtained, and it was calculated as follow:  
Production rate (mM/h) =
12
)(1)(2
TT
mMreuterinmMreuterin
−
− . 
As shown in Figure 4.5, the reuterin production rate reached a maximum of 10.9 mM/h 
(811 mg/L.h-1) at 6h of incubation and sharply decreased thereafter.  
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Figure 4.5  Production rate of reuterin during incubation of DPC16 in glycerol-MSR broth under 
standardised conditions. 
Having known from previous biomass determination (Section 4.3.3) that the MRSg was 
produced from 11 g/L of DPC16 resting cells, then the production rates of reuterin 
(monomer MW = 74 g/mol) were translated into specific production rate as follow:  
Specific production rate =
)/(16
)(
LgweightdrycellDPC
mMdsynthesizereuterin x h-1. 
A maximal specific rate of 0.99 mmol/g CDW.h-1 (73.7 mg/g CDW.h-1) was obtained at 
6h of incubation and the total reuterin produced from biomass was 420.4 mg/g CDW 
after 18h incubation in glycerol supplemented MRS broth. 
4.3.4 Reuterin and antimicrobial activity 
Figure 4.6 integrates the reuterin produced in MRSg with its antimicrobial activity 
through the kinetic profile. It shows that the presence of low level of reuterin (<30 mM 
for most pathogens and <14 mM for S. aureus) produced in the early hours of 
incubation, inhibits pathogens at low levels, however, as reuterin accumulated beyond a 
certain threshold (specific tolerable level of pathogen), the inhibition of pathogens 
Chapter 4                    Kinetics of DPC16 growth and reuterin production 
 67 
largely increased. This result complies with the primary antimicrobial test of MRSg as 
discussed in Section 3.3.2. Thus, a relationship can be proposed between accumulated 
reuterin and the antimicrobial activity of MRSg. This result also confirms that the strong 
antimicrobial activity exhibited by MRSg at 8h incubation and thereafter (6h in case of 
S. aureus) was largely due to production of reuterin, as seen in the development of 
antimicrobial activity. Additionally, differential growth inhibition has revealed that the 
reuterin activity on pathogens is strain specific, where S. aureus is more susceptible to 
reuterin than the other pathogens tested.  
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Figure 4.6  Antimicrobial activity of MRSg, expressed as concentration of reuterin, exhibited 
during the secondary fermentation of glycerol in MRS broth.  
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4.4 Discussion  
The investigations in this chapter covered three parts. The first part reported the growth 
kinetics of L. reuteri DPC16 in batch culture under standardised in vitro conditions of 
anaerobic incubation in pre-reduced MRS broth at 37°C. The second part measured rate 
of reuterin production from glycerol, in both MRSg and SGF. The last part of this 
chapter investigated the relationship between reuterin in MRSg and its antimicrobial 
activity, and provided evidence that reuterin production is the major factor responsible 
for the strong antimicrobial activity of MRSg.  
A 20h incubated DPC16 culture has shown a well-grown population with viable cells 
reaching a total number of 4.23 x 109 CFU/mL in a total biomass of 5.5 g/L. The 
biomass result indicated that the two-fold concentrated DPC16 resting cells, used for 
glycerol fermentation, contained about 11 g/L of biomass. This is consistent with the 
data reported by Talarico et al. (1988), where 10 mg/mL of CDW was used to produce 
reuterin.   
The culture pH was observed to drop from 6.50 to 4.44 during incubation, which 
indicated the growth of DPC16 as evidenced by production of metabolic by-product 
(SCFA). According to Lu (2007), lactic acid produced by L. reuteri DPC16 in modified 
MRS broth grown under optimal anaerobic conditions reached a maximum of 2.6 to 2.8 
g/L after 16h of growth. Based on the viable cell count and weight of dried cells, two 
correlation curves were developed, namely optical density (OD620) with viable cells and 
optical density with biomass (CDW), to characterise the culture growth. There was a 
good linear relationship between the cultural optical density and the biomass. Such 
linear correlation of L. reuteri culture has been reported previously by El-Ziney et al. 
(1998) and Rasch et al. (2002 b). 
A time course produced a sigmoidal growth curve for DPC16 in MRS broth. It showed 
that the length of the lag phase was 8-10h; the exponential phase was initiated from 10h 
and continued over a 4-6h period of linear growth; then the culture entered the 
stationary phase where the growth curve levelled. The slope of the linear range in the 
exponential phase was determined as 0.137 h-1. By converting the optical density values 
into cell dry weight in the linear range of the exponential phase, the specific growth rate 
of DPC16 culture was mathematically described as 0.6 h-1, with a population doubling 
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time of 1.16h. Talarico et al. (1990) reported a generation time of approximately 66 min 
when growing a strain of L. reuteri on glucose in a modified Lactobacillus carrying 
medium. El-Ziney et al. (1998) reported a specific growth rate of 0.43 h-1 in a batch 
culture fermentation of L. reuteri 12002 in a medium containing 60 mM of glucose.  
In this study, production of reuterin from glycerol was measured to characterise the 
production kinetics during a secondary fermentation. Glycerol utilisation in both MRSg 
and SGF were observed from the beginning of the secondary fermentation; however, the 
amount of reuterin produced varied greatly between the two supernatants. Reuterin was 
detected in MRSg but not in SGF, even though some decrease of glycerol concentration 
was observed in SGF. As mentioned in Section 2.4.4, reuterin is produced as an 
intermediate during glycerol dissimilation, and it can be further reduced to 1,3- 
propanediol. However, according to Talarico et al. (1988, 1990), L. reuteri is unique in 
its ability to accumulate reuterin in cultural supernatant, and no reuterin was detected 
over the entire incubation period in producing SGF. Thus it can be considered that 
reuterin was not produced in glycerol-water fermentation, even though other 
by-products (i.e. 1,3- propanediol) were not measured in this study. This small amount 
of glycerol was assumed to have auto-diffused (i.e. been absorbed) into the DPC16 cell 
until a saturation concentration was reached. Based on this assumption, glycerol 
utilisation in MRSg was calculated, and together with the concentration of reuterin, a 
series of kinetic parameters were obtained.  
From the kinetic profile of MRSg supernatants, it was found that 85.8 mM (23.8% of 
the total supplementation) of glycerol was utilised, other than auto-diffusion, during the 
production MRSg, where a total amount of 62.5 mM of reuterin was produced at the 
end of the incubation, accounting for the 72.8% of the utilised glycerol. Again, it was 
observed that the amount of glycerol utilised was not equal to the reuterin synthesised. 
According to Talarico et al. (1988), 1 mol of glycerol is transformed into 1 mol of 
reuterin. The difference observed here may be due to further reduction in some of the 
synthesised reuterin, as mentioned by Talarico et al. (1990). However, the exact 
mechanism of this was not investigated further.  
Varied magnitudes of glycerol bioconversion to reuterin in glucose-containing media 
have been previously reported on different strains of L. reuteri. El-Ziney et al. (1998) 
obtained 38 arbitrary units/mL of reuterin in batch culture containing 60 mM of glucose 
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and 150 mM of glycerol. Luthi-Peng et al. (2002 b) obtained a total of 24.32 mM of 
reuterin in a L. reuteri ATCC53608 culture accounting for 40.5% of the supplemented 
glycerol (60 mM). The differences in reuterin production within L. reuteri species is 
reported to be strain specific (Spinler et al., 2008).  
In the present study, it was also found that reuterin was produced as early as 2h in the 
secondary fermentation and the production rate continued to increase until a maximum 
of 10.9 mM/h (811 mg/L.h-1) was reached at 6h of fermentation, Then the production 
rate decreased sharply with a constant reuterin concentration for the rest of the 
fermentation process. A similar result was reported by El-Ziney et al. (1998) who 
detected reuterin after 2h of incubation in a co-culture fermentation of glycerol and 
glucose, and an exponential increase occurred between 2-4h, after which glycerol 
continued to decrease while the reuterin remained constant. Rasch et al. (2002 b) 
studied growth kinetics of a batch culture of L. reuteri with glycerol-supplementation, 
and reported that there is no decease in reuterin concentration from maximum level with 
time.  
Based on the biomass quantification (11 g/L), the reuterin production was further 
translated into a maximum specific production rate of 73.7 mg/g CDW.h-1 obtained at 6h 
of incubation, and the total reuterin produced from biomass was 420.4 mg/g CDW 
during incubation in glycerol supplemented MRS broth. 
Thus, the results of this study have shown that the bioconversion of glycerol to reuterin 
only occurred in glycerol-MRS fermentation whereas no reuterin was produced in the 
glycerol-water fermentation, based on the reuterin production in DPC16 supernatants of 
MRSg and SGF. Even though some L. reuteri strains may be able to produce reuterin in 
glycerol-water medium, this study has provided evidence that this DPC16 strain of L. 
reuteri does not have this capability. For this strain, as mentioned by Talarico et al. 
(1990), fermentable carbohydrate (glucose) is essential for metabolism and subsequent 
reuterin production, if glycerol is provided. Consequently, SGF, the supernatant 
produced from glycerol-water fermentation, did not show any antimicrobial activity, 
which may be attributed to the lack of reuterin as well as SCFA from cell metabolism.  
On the contrary, MRSg, the supernatant containing reuterin has shown strong 
antimicrobial activity. Based on the observation of a similar sigmoidal pattern of 
development in both reuterin synthesis and antimicrobial activity, reuterin concentration 
Chapter 4                    Kinetics of DPC16 growth and reuterin production 
 71 
in MRSg profile was integrated with its antimicrobial activity, and a relationship 
between reuterin and the antimicrobial activity was established. Additionally, it was 
observed that the most susceptible pathogen, S. aureus, responded to the increase in 
reuterin production in the same way it responded to the increase in antimicrobial 
activity observed in MRSg. These results have provided further evidence that the major 
antimicrobial component in MRSg that accounted for its potent antimicrobial activity is 
very much likely to be reuterin. However, because reuterin was not purified in this 
thesis, the true antimicrobial activity of pure reuterin remains to be explored. 
Finally, in response to the assumption of pathogen threshold as discussed in Chapter 3 
(Section 3.4), if reuterin was the major antimicrobial factor, the sudden increase of 
pathogen growth inhibition may be due to a specific reuterin-tolerance threshold of each 
pathogen, where accumulated reuterin has to exceed a certain level to reach total 
inhibition. Again, this assumption remained unexplored because there was no purified 
reuterin available in this study.  
In summary, the growth kinetics and reuterin production kinetics of L. reuteri DPC16 in 
batch culture under standardised in vitro conditions were studied. The growth of this 
strain had a 8-10h lag phase, followed by a 4-6h exponential phase with a specific 
growth rate of 0.6 h-1 (or a doubling time of 1.16h), and resulted in a total number of 
viable cells of 4.23 x 109 CFU/mL weighing 5.5 g/L and a pH drop from 6.50 to 4.44, 
after 20h of anaerobic incubation at 37°C in pre-reduced MRS broth. The reuterin 
production from glycerol bioconversion was analysed with supernatants harvested from 
a secondary fermentation of DPC16 resting cells in either growth medium of 
glycerol-MRS or non-growth medium of glycerol-water, namely MRSg and SGF 
respectively. The results showed that, in MRSg, 72.8% of used glycerol was converted 
to reuterin with a maximum production rate of 10.9 mM/h (or a maximum specific 
production rate of 73.7 mg/g CDW h-1) at 6h of secondary fermentation and a total 
amount of 62.5 mM of reuterin accumulated in the supernatant. However, there was no 
reuterin detected in SGF, even though glycerol has been absorbed by the concentrated 
resting cells.  
The kinetics of growth and reuterin production studied in this chapter were obtained 
under standard in vitro conditions where sufficient nutrients were provided and no 
natural competition was present. The actual bacterial growth in the host GI tract may be 
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totally different in terms of specific growth rate and reuterin production. However, these 
in vitro findings may provide evidence for industrial application of products from this 
DCP16 strain, based on the examined safety status.  
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Chapter 5 
Evaluating the impacts of Lactobacillus reuteri DPC16 on mucin 
degradation and on the growth of other probiotics, in vitro 
5.1 Introduction 
The human GI tract harbours a variety of abundant microorganisms, namely the 
gastrointestinal microflora. There is a growing consensus that the composition of the 
microflora can affect human health and cause disease due to their close association 
during co-evolution (Hooper and Gordon, 2001; Magalhaes et al., 2007). The bacterial 
inhabitants of the human gastrointestinal tract constitute an enormously complex 
ecosystem with an approximate total number of 1014 CFU/mL, representing more than 
500 species of bacteria (Magalhaes et al., 2007). These microorganisms perform 
extremely diverse metabolism, growing on food components ingested or secreted by the 
host, converting substances into compounds beneficial or detrimental to the host, and 
live together in symbiotic or antagonistic relationships (Mitsuoka, 1992 a, 1992b). A 
predominance of harmful bacteria leads to aging and various severe bowel diseases, 
while “good” bacteria subsequently act as scavengers against the induced damages. 
Hence the microbial interaction is a major factor in regulating the indigenous intestinal 
microflora (Simon and Gorbach, 1986). A healthy gastrointestinal microbial regulation 
can be achieved by stimulating beneficial bacteria to locally synthesise enzymes, 
organic molecules, and short chain fatty acids, which inhibit the proliferation of 
detrimental bacteria hence maintaining a satisfactory balance of the local microflora 
towards host health and longevity. To qualify to be a probiotic bacterium, a novel 
indigenous bacterial strain must demonstrate efficacy of being non-pathogenic to other 
members of the local microflora and to the host, and preferably possess functional 
characteristics to suppress pathogenic bacteria as well as conferring other benefits to the 
host (Donohue and Salminen, 1996; Saarela et al., 2000; Puupponen-Pimia et al., 2002).  
The intestinal mucosa facing the intestinal lumen possesses a layer of mucus, which is 
hydrophilic and has a complex structure with a viscoelastic property (Hoskins et al., 
1985). This mucus immobilises nutrients and provides a microhabitat for colonization 
by a majority of the local microflora. The mucus is synthesised by the underlying 
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epithelia, and contains a high molecular weight (~103 kDa) glycoprotein, termed mucin 
(Bengmark and Jeppsson, 1995; Smith et al., 1995; Macfarlane et al., 2005). Mucin is 
composed of a peptide core rich in serine and threonine residues, which are decorated 
by tandem oligosaccharide repeats via O- or N-glycosidic bonds. The exterior 
oligosaccharides that tightly wrap around the peptide core are terminated by sialic acids 
or sulphate groups, which together with the flanking oligosaccharide can exhibit 
antigenic specificity for mucoadhesivity (Hoskins et al., 1985; Rosendale, 1997; 
Derrien et al., 2004; Bansil and Turner, 2006). The mucus structure acts as an intestinal 
protective barrier that tightly controls the trans-cellular and para-cellular transports by 
membrane pumps, ion channels and tight junctions. It also regulates the host defence 
mechanisms at the mucosal interface with “the outside world” (Baumgart and Dignass, 
2002). By covering the underlying epithelial enterocytes, mucus provides protection 
against potential damages caused by corrosive acids, bile salts and enzymes of digestive 
juice (Allen et al., 1984; Zhou et al., 2001; Macfarlane et al., 2005), luminal flow 
shearing forces generated by the digestive process from the stomach duodenum and the 
gut lumen (Smith and Podolsky, 1986; Smith et al., 1995), and invasion by pathogenic 
microorganisms (Cohen and Laux, 1995; Gibson et al., 1997).  
However, the mucus can be damaged by colonised pathogenic bacteria through 
degrading the mucin side chains. Studies have reported that a viable subpopulation of 
faecal flora collected from healthy human subjects is capable of degrading mucin based 
on their capacity to grow on mucin-containing basal media (Hoskins and Boulding, 
1981; Hoskins et al., 1985; Macfarlane and Gibson, 1991; Gibson et al., 1997; 
Ruas-Mediedo et al., 2008). Some of these subpopulations, belonging to the genera of 
Ruminococcus, Bacteroides, Clostridium and Bifidobacterium, have been shown to 
secret extracellular sialidase and a series of glycosidases, which recognise the terminal 
receptors of mucin and exfoliate the oligosaccharides. Impaired mucin structure, from 
enzymatic degradation, may provide opportunity for invading microorganisms to 
traverse to the underlying enterocytes, damage the cells, and secret toxic and 
inflammatory compounds into the blood vessels which circulate throughout the body. In 
addition, mucin degradation releases monosaccharides and amino acids, and these 
nutrients can be utilised directly by those invading pathogens to worsen the damage. 
Ruseler-van Embden et al. (1995) claimed that any change in mucus content and 
structure may compromise the mucosal defence barrier and increase the numbers of 
bacteria adhering to the enteric cell surface, and hence is regarded as pathogenic and 
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locally toxic. Therefore, mucin degradation has been considered as a useful indicator for 
distinguishing between commensal and pathogenic bacteria, and thus can be used as a 
safety assessment for potential probiotics (Magalhaes et al., 2007). Several probiotic 
strains including Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus 
rhamnosus and Bifidobacterium lactis have been cultured on hog gastric mucin, in vitro, 
and none has been reported to degrade gastric mucin glycoprotein, thus far (Ruseler-van 
Embden et al., 1995; Zhou et al., 2001).  
Lactobacillus reuteri is believed to be one of the few true autochthonous Lactobacillus 
species in humans (Reuter, 2001), and resides frequently as a heterofermentative lactic 
acid producing-bacterium in the GI tract of many species of animals. Strains of L. 
reuteri have been shown to possess high affinity for mucin binding via 
membrane-associated protein (Satoh et al., 1999; Jonsson et al., 2001), and no 
observable mucin degradation was reported in L. reuteri-primed mice after oral 
administration (Norin and Casas, 1999). Bifidobacterium is another genus of common 
inhabitants of the gastrointestinal tract. This genus has received special attention 
because of its health-promoting effects and long history of safe use in the functional 
food industry (Ruseler-van Embden et al., 1995; Salminen et al., 1998 a), even though 
several strains (i.e. B. bifidum, and B. longum) have been reported for mucinolytic 
activity due to the possession of the genes accountable for extracellular glycosidase 
(Ruas-Mediedo et al., 2008). Bifidobacterium lactis HN019 is a patented probiotic 
strain trade-marked as B. lactis DR10, which has been intensively studied for function, 
safety and production characteristics important to its ability to function as a probiotic 
(Gopal et al., 2005). This strain is now commercially available in selected dairy 
products (Activate.co.nz, 2008). In particular, this DR10 strain has been studied for 
mucus degradation and found to be safe for the gastrointestinal mucosal environment 
(Gopal et al., 2001; Zhou et al., 2001). Hence, this strain was used as a reference culture 
indicating non-mucin-degradation in the mucus degradation study for DPC16 cultures 
in this study.  
The objectives of this chapter were to provide preliminary safety assessment by 
evaluating the effects of L. reuteri DPC16 cultural supernatants, especially MRSg, on 
the growth of some common commensal probiotic bacteria; and determining if this 
strain is capable of degrading mucin.  
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5.2 Materials and Methods 
5.2.1 The effect of DPC16 supernatants on growth of the selected probiotic 
strains 
The probiotic bacteria Lactobacillus acidophilus (L. acidophilus), Lactobacillus 
plantarum (L. plantarum), Pediococcus acidilactici (P. acidilactici) and Bifido- 
bacterium lactis DR10 (B. lactis DR10) were kindly provided by BRNZ, as 30% 
glycerol stocks stored at -80°C. The stock cultures were activated, sub-cultured and 
enumerated following the method of described in Section 3.2.2 and 4.2.1, except that 
DR10 was incubated for 48h. The subcultures were then used as master inocula for 
subsequent assays (these master inocula were always freshly made from stock prior to 
assay).   
Based on the enumeration, an inoculum containing ca. 104 CFU/mL of each probiotic 
strain was prepared from the master inocula, and subsequently inoculated into 
pre-reduced MRS broth in 96-well microtitre plates, in quadruplicate. By incubating the 
probiotic cultures under anaerobic conditions with shaking (250 RPM) at 37°C, and 
measuring the OD620 at designated time intervals, a growth curve of each probiotic 
culture was developed spectrophotometrically.  
DPC16 cultural supernatants, which had been previously tested for antimicrobial 
activity against selected pathogens (Chapter 3), were used to evaluate their effects on 
the growth of selected probiotic strains following the method described in Section 3.2.4 
(with exception of longer incubations: B. lactis DR10 was incubated for 48h; the other 
probiotic strains were incubated for 24h) in the rich growth medium of pre-reduced 
MRS broth. The DPC16 cultural supernatants as listed in Table 3.1 and their 
pH-adjusted counterparts (except SGF) were also investigated.  
While a preliminary antagonistic assay was processed with undiluted supernatants, 
MRSg-8h (containing reuterin as proven in Chapter 4) and its pH adjusted counterpart 
were further studied in a highly diluted form [4000-fold, the probiotic 
growth-stimulatory concentration of methylglyoxal as introduced by Rosendale (2007)] 
to assess their stimulatory effects on the growth of target probiotics in a time course 
investigation, as in Section 3.2.5.  
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5.2.2 Mucin degradation 
L. reuteri DPC16 cultures from incubation in pre-reduced MRS broth, and from 
secondary fermentation using concentrated resting cells in glycerol-supplemented MRS 
broth, were used to test their mucinolytic activity on porcine gastric mucin (PGM), in 
vitro. This assay followed the method introduced by Zhou et al. (2001) with some 
modifications.  
5.2.2.1 Mucin purification 
Partially purified porcine gastric mucin (Type III, Sigma; USA) with 0.5-1.5 % (w/v) 
bound sialic acid was further purified by stirring 10 g in 500 mL of PBS for 1h. The pH 
value of this solution was adjusted to 7.2 using 0.1 M NaOH. With addition of a few 
drops of toluene for preservation, this solution was continuously stirred for another 24h 
at room temperature, and was subsequently centrifuged at 10,000 x g for 10 min at 4°C. 
The supernatant was removed and immediately put in an ice bath. The pellet was 
washed with pre-chilled (4°C) ethanol (99%, molecular biology grade, J.T. Baker 
Chemical Co.; USA) and re-centrifuged to collect the resulting supernatant. This 
resulting supernatant was added to the previously collected supernatant to obtain the 
final supernatant, which contained dissolved mucin. Pre-chilled ethanol was again 
added to the cooled final supernatant to a final concentration of 60% (v/v). The 
precipitated mucin was collected and washed two more times with ethanol to remove 
trace sialic acid and other salts. The final precipitate was then rotary-evaporated to 
remove ethanol and dissolved in distilled water. This mucin solution was frozen and 
then freeze-dried as described in Section 3.2.2, and the lyophilized mucin was used as a 
source of purified mucin for the mucinolytic assay in this chapter. 
5.2.2.2 Basal medium for anaerobic cultures 
A basal medium was prepared according to the methods of Zhou et al. (2001), as shown 
in Table 5.1. L-cysteine-HCl was filter-sterilized and added into the medium after 
autoclaving at 120°C for 15 min, followed by pH adjustment using 0.1 M NaOH. The 
final pH value of this medium was 7.2 ± 0.2. Purified PGM and/or glucose were 
supplemented as required to a concentration of 10 g/L.  
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Table 5.1  Ingredients of basal medium for mucin degradation assay.  
Ingredients Amount (g per litre of distilled water) 
Tryptone (Bacto, BD; USA) 7.5 
Trypticase Peptone (Bacto, BD; USA) 7.5 
Yeast Extract (Fluka, EU) 3.0 
Beef extract (Acumedia, Michigan, USA) 5.0 
NaCl (Sigma, USA) 5.0 
K2HPO4 (BDH, USA) 2.3 
KH2PO4 (UniVar, USA) 0.5 
MgSO4•7H2O (Sigma, USA) 0.5 
L-cysteine-HCl 0.5 
Resazurin  (anaerobic indicator) 0.002 
Medium pH value: 7.2 ± 0.2 
 
5.2.2.3 Bacterial cultures 
The cultures of the potential probiotic strain L. reuteri DPC16 and the reference strain B. 
lactis DR10 were prepared anaerobically. Briefly, L. reuteri DPC16 was prepared as a 
20h culture in pre-reduced MRS broth and as an 8h culture from secondary fermentation 
with 11 g/L of resting cells in glycerol-supplemented MRS broth. These DPC16 cultures 
were designated as LR and LRg, respectively. The 48h culture of the reference strain B. 
lactis DR10 was prepared in pre-reduced MRS broth, and designated as BbL. 
A mucinolytic faecal culture was prepared from a fresh faecal sample of a healthy 
young adult female who had not received antibiotics for the previous 3 months. 
Preparation of the faecal sample followed the method described by Darrien et al. (2004) 
with some modifications. Briefly, the fresh faecal samples were collected in a sterile 
disposable stomacher blender bag (Bagpage+ 400, Interscience, France), weighed and 
suspended to 10% (w/v) in anaerobic Ringer solution (containing 8.6 g/L NaCl, 0.3 g/L 
KCl, 0.33 g/L CaCl2, and 0.5 g/L of L-cysteine in distilled water, pH 7.2; diluted with 
water to quarter strength prior to use). The faecal suspension was homogenized twice, 
using a Stomacher Blender (Masticator 400 lab blender, IUL instrument; Spain) for 
2min each time, in a sealed stomacher blender bag. After 5 min standing, the faecal 
liquid was centrifuged at 600 x g for 5 min at 4°C. The supernatant was collected and 
stored at -20°C as a faecal flora suspension until the time of use (maximum storage 
period of one month).  
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Subsequently, 1% (v/v) of the faecal culture was inoculated into BHI broth and 
incubated at 37°C for 24h. This subculture, enumerated by haemocytometer to contain 
approximately 2 x 1010 CFU/mL of total bacteria, was used as a positive control for the 
mucin degradation assay, and designated as FF. An aliquot of this subculture was 
heat-killed at 120°C for 15 min, and used as a negative control, designated as HFF.   
5.2.2.4 Mucin degradation assays 
The quantitative mucin degradation assay in basal media and the qualitative assay on 
agar plates were both based on the methods of Zhou et al. (2001). Cultures of the LR, 
the LRg, the BbL, and the controls of fresh faecal flora (FF) and the heat-killed faecal 
flora (HFF) were all included in this assay. Briefly, 1% (v/v) of each culture was 
incubated at 37°C for 48h in basal media containing either PGM (10 g/L) with or 
without glucose (10 g/L), or glucose (10 g/L) only. Basal medium containing no 
inoculum but PGM or glucose supplementations were used as blank or medium controls. 
At the end of incubation, the cell concentrations in the different media were measured 
by OD at 620 nm, and the pH changes were measured. Each culture, in every designated 
growth medium, was assayed in triplicate. 
To confirm the results, a mucin degradation assay on agar plates was conducted to 
demonstrate the mucinolytic activity more objectively, using the method described by 
Colina et al. (1996) with some modifications. Briefly, purified PGM (10 g/L) was 
incorporated into a basal medium containing agarose (15 g/L) (DNA-grade, BDH, 
Electran, England) with or without glucose (10 g/L). After allowing this medium to 
harden, aliquots of each test culture were inoculated onto the surface of the agarose 
medium using the drop plate technique. The plates were allowed to dry, and then were 
incubated anaerobically at 37°C for 72h. After incubation, all plates were stained with 
Coomassie Blue R-250 staining solution*
                                                        
* Like the use of amido black as described elsewhere (Colina et al., 1996; Zhou et al., 2001), 
Coomassie blue was employed in this study for detecting the appearance of core protein, exposed 
from polysaccharide wrapping, of degraded mucin. 
 [containing per L, 2.5 g of Coomassie Blue 
R-250; 455 mL of analytical grade ethanol; 455 mL of distilled water; and 100 mL of 
glacial acetic acid (100%, BDH; UK)] for 45 min, and subsequently washed with 1.2 M 
acetic acid to de-stain until the discoloured zone appeared. Mucin degradation was 
indicated by the appearance of the mucin lysis zone around the colonies, and the 
diameters of zones were measured from triplicate angles.  
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5.3 Results  
5.3.1 The effects of DPC16 supernatants on growth of the selected probiotic 
strains 
A growth curve of each probiotic strain was initially developed in pre-reduced MRS 
broth, as shown in Figure 5.1. Most probiotic cultures showed a similar growth pattern 
to L. reuteri DPC16 (Figure 4.2), except for B. lactis DR10 which had as longer period 
of lag phase to 18h. The cell concentration of each strain, reflected by the OD620 at the 
endpoint of incubation, was also in a similarly high level to that of the L. reuteri DPC16 
in its stationary phase.  
 
 
 
 
 
 
 
 
 
Figure 5.1  Growth curves of probiotic strains in MRS during anaerobic incubation at 37°C. Data 
points are mean of OD620 with SEMs represented as vertical bars (n=4). A regression line linearly 
fitting the exponential phase is plotted for each strain, with a mathematic equation indicating the 
slope.  
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The preliminary test on effects of selected DPC16 supernatants on the growth of target 
probiotic strains is shown in Figures 5.2 and 5.3. No significant growth inhibition was 
observed from any of the tested DPC16 supernatants (P>0.05), regardless of pH 
adjustment. Additionally, as seen in Figure 5.4, the time course of probiotic strains 
showed that the 4000-fold-diluted MRSg-8h had no significant stimulatory effect on the 
growth of any of the tested probiotics, which suggests that the reuterin, at this 
concentration, does not stimulate the growth of the tested probiotic strains.  
 
 
 
 
 
 
 
 
 
 
Figure 5.2  Effects of MRSc, FZMRSc and their pH-adjusted counterparts on the growth of 
selected probiotic cultures. Values are the mean percentage of inhibition relative to untreated 
controls, calculated from OD620 of probiotic strains with or without treatments, with SEMs 
represented by vertical bars (n=9).  
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Figure 5.3  Effects of MRSg, SGF and pH-adjusted MRSg on the growth of selected probiotic 
cultures. Values are the mean percentage of inhibition relative to untreated controls, calculated from 
OD620 of probiotic strains with or without treatments, with SEMs represented by vertical bars (n=9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4  A time course of probiotic strains treated with and without MRSg-8h or its pH- 
adjusted counterpart. Data points are means OD620 of quadruplicate measured at time intervals 
during incubation, with SEMs represented by vertical bars.  
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5.3.2 Degradation of mucin in liquid media 
The growth of LR, LRg, BbL and the faecal flora controls in different media were 
indicated by the changes of OD620 (Figure 5.5) and the pH values (Table 5.2) after an 
anaerobic incubation for 48h. No growth occurred in the heat-killed faecal flora control. 
A statistical analysis showed that there was no significant difference in the growth of 
BbL (P= 0.194) in the medium containing purified PGM as the sole carbon source, 
when comparing with the heat-killed faecal flora control. Negligible growth (OD620<0.1) 
in LR and LRg was observed, whereas an apparent growth of the faecal flora in the 
same medium was detected (P=0.004). All cultures showed good growth in 
glucose-containing media, regardless of the presence of PGM. There was no pH change 
detected in any culture incubated in the basal medium containing no carbohydrate, nor 
in the heat-killed faecal flora control. The pH decreases of L. reuteri cultures (LR or 
LRg) were detected only in media containing glucose, and were similar to the reference 
culture (BbL). The faecal flora culture, however, showed lowered pH values in growth 
media with or without glucose.   
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Figure 5.5  Growth of potential probiotic cultures and faecal flora cultures in basal medium 
supplemented with designated carbohydrate sources. Bar values are means of triplicate OD620 
readings measured at the end of the 48h incubation, with SEMs represented by vertical bars. 
Abbreviations of culture inocula: LR, 20h culture of DPC16 in MRS broth; LRg, 8h culture of 
DPC16 in glycerol-supplemented MRS using concentrated resting cells; BbL, 48h culture of B. 
lactis DR10; FF, 20h incubated faecal flora culture; HFF, heat-killed faecal flora culture; PGM, 
purified porcine gastric mucin.  
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Table 5.2  The final pH values of cultures incubated in various media comparing to their original 
cultures which indicate the starting pH values. 
 Original Cultural pH PGM + Glucose PGM Glucose  Basal Medium  
LR 4.4 4.4 7.2 4.3 7.2 
LRg 4.3 4.3 7.2 4.3 7.2 
BbL 3.9 3.8 7.3 3.9 7.3 
FF 6.7 4.1 5.1 4.1 7.2 
HFF 6.9 7.1 7.4 7.2 7.1 
 
5.3.3 Degradation of mucin on agarose plate 
Figure 5.6 shows the results of the mucin degradation assay on agarose plates 
containing PGM only or PGM with glucose. Only the faecal flora culture grew on the 
plate containing PGM only; whereas colonies of the other cultures appeared on the 
medium where glucose was available. No growth of the HFF control was observed on 
either of the agar media. More objectively and with better resolution, the Coomassie 
blue-staining showed significant mucinolytic activity of faecal flora on both media. 
Again, no mucin degradation was observed for any other cultures. Measurements show 
that the faecal flora developed a lysis zone with diameter of 1.68 cm on PGM-only 
medium, and a smaller lysis zone with a diameter of l.16 cm on medium containing both 
PGM and glucose. It is worth noting that the mucin degradation of faecal flora on 
agarose medium containing both PGM and glucose was less intensive than that on 
medium containing PGM only. 
 
 
Figure 5.6  Degradation of mucin on agarose plate supplemented with PGM only (left) and PGM 
with glucose (right). The plates were stained with Coomassie-blue and de-stained with 1.2 M acetic 
acid. The discoloured zones indicate mucinolytic activity of the faecal flora culture. Abbreviation: 
PGM, purified porcine gastric mucin; NG, medium containing no glucose but PGM; G, medium 
was supplemented with both PGM and glucose.  
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5.4 Discussion 
Lactobacillus reuteri belongs to the genus Lactobacillus, which has a long history of safe 
usage in various food industries. There is no report for L. reuteri or the previously 
classified L. fermentum of any clinically adverse effect (Wolf et al., 1995, 1998). L. 
reuteri has also been demonstrated in vitro, to be able to resist pH 1.5 and 0.3% oxgall 
bile (Kim et al., 2006; Casas and Dobrogosz, 2000), to adhere strongly to epithelial 
mucus (Satoh et al., 1999; Jonsson et al., 2001) and to colonise the human GI tract for up 
to 2 months (Wolf et al., 1995). Additionally, L. reuteri has been found, in a probiotics 
screening test, to have no adverse effect on normal GI bacteria (Jacobsen et al., 1999). 
Hence, L. reuteri species can be generally regarded as safe for the host.  
In this chapter, experiments were conducted to assess the safety of this novel DPC16 
strain of L. reuteri, in aspects of effect (inhibitory of stimulatory) of its cell-free 
supernatants on the growth of selected commensal probiotic bacteria. In addition, the 
DPC16 cultures from both reuterin-producing and non-reuterin-producing media were 
tested for mucinolytic activity.  
A preliminary antagonistic assay was carried out using selected DPC16 supernatants, 
which had shown antimicrobial activities (except SGF-2h) against selected pathogens. 
The results showed that, although some of these supernatants were able to inhibit the 
growth of pathogenic bacteria (as seen in Chapter 3), no significant inhibitory effect on 
common probiotics was detected. The results may also suggest that there was no 
bacteriocin synthesised by this strain, which targets closely related LAB species as seen 
in reutericin 6 produced by L. reuteri LA6. Thus, they can be, so far, regarded as safe to 
the tested normal commensal intestinal microflora. This result is consistent with the 
published finding of Jacobsen et al. (1999) on another strain of L reuteri (DSM 12246). 
A recent study on compatibility of four strains of L. reuteri (ATCC 55730, ATCC PTA 
6475, ATCC PTA 4659 and ATCC PTA 5289) with other common Lactobacillus strains 
showed that the L. reuteri strains did not potently inhibit the growth of most of the 
tested Lactobacillus strains, except for L. casei ATCC 334; and also there was no 
inter-strain variation among the four L. reuteri strains, in terms of inhibition of other 
Lactobacillus species (Spinler et al., 2008).  
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In addition, the result from this study also showed that the reuterin-containing 
supernatant of MRSg did not have a stimulatory effect on the growth of the tested 
probiotic bacteria, even in a highly diluted form. This suggests that reuterin, at the same 
dilution, is unlike the structurally similar compound of methylglyoxal and may not have 
a similar stimulatory effect on probiotics’ growth  
The gastrointestinal mucosa plays an important role as a physical barrier in preventing 
potential pathogens from translocation and subsequent infection to extra-intestinal 
epithelia and tissues (Carlsson, 1993). The ability to degrade the mucus basic structure 
framework, mucin, is considered as one of the valuable indicators of potential 
pathogenicity and local toxicity of lumen bacteria (Ruseler-van Embden et al., 1995; 
Donohue and Salminen, 1996; Salminen et al., 1998 a). A series of extracellular 
enzymes including sialase, sulfatases, glycosidases, galactosidase, and N-acetyl- 
glucosaminidase, synthesised by a variety of enteropathogens, have been reported to be 
responsible for extensive mucin degradation (Hoskins et al., 1985; Colina et al., 1996; 
Darrien et al., 2004), and bacteria capable of producing such enzymes are also 
recognized to be pathogenic.  
In this study, an enzymatic assay was not performed; instead, commercially available 
porcine gastric mucin was used to assess the mucinolytic activity of two L. reuteri 
DPC16 cultures (reuterin-producing and non-reuterin-producing) in a basal medium, 
using a previously-assessed mucinolytic-negative strain of B. lactis DR10 as a reference 
and human faecal flora as a positive mucin-degrading control.  
DPC16 cultures inoculated in the basal medium, where purified mucin was the only 
carbohydrate source, exhibited a negligible growth accompanied by stable pH. These 
results were similar to the reference strain of B. lactis DR10. However, the positive 
control of the faecal flora grew reasonably well in the same medium. Addition of 
glucose into this mucin-containing medium triggered the normal growth of all cultures 
containing viable inocula, and large pH drops. This result shows that the DPC16 
cultures, regardless of reuterin presence, behaved similarly to the mucinolytic-negative 
reference strain in that they cannot utilise mucin as a sole energy source due to lack of 
enzymes required to metabolise the components of complex mucin glycoprotein. For 
the positive control, the growth of faecal flora occurred in media with or without 
glucose, which suggests that the faecal flora culture is capable of utilising both mucin 
and/or glucose by its respective subpopulations.  
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To confirm the results of the mucin degradation obtained in liquid media, the 
mucinolytic activity was tested on agarose plates. The results were consistent with the 
findings from the liquid media in that the DPC16 cultures were unable to grow on 
medium supplemented with PGM only. Similar result was observed with the reference 
culture. In contrast, faecal flora colonization was apparent on both the PGM-containing 
plates with or without glucose. By using the staining and de-staining process, a large 
discoloured zone around the colony of faecal flora was observed. This indicated the 
presence of proteins within the discoloured zone. As previously introduced (Section 5.1), 
mucin structure is composed of a protein core attached to, and tightly wrapped by, 
repeated links of polysaccharides. The presence of protein suggests that the 
polysaccharide framework of mucin has been demolished, and the core protein 
composition was exposed. Hence, according to Zhou et al. (2001), it indicates 
mucinolytic activity. No DPC16 cultures or reference culture showed such activity on 
either medium containing glucose or not, which corresponds to the result of the mucin 
degradation assay in liquid media. Hence, this DPC16 strain of L. reuteri does not 
possess mucinolytic activity. This result is consistent with the previous finding of Norin 
and Casas (1999), who studied the development of microflora-associated characteristics 
of L. reuteri mono-colonised rats, and reported that no observable mucin degradation 
occurred.  
Levels of mucin degradation by the faecal flora were different on agarose media with 
and without glucose. It was noted that the mucinolytic zone on glucose-supplemented 
medium (containing PGM) was smaller and less intense than the zone that appeared on 
PGM-only medium. This may indicate nutrient-dependence of subpopulations in the 
faecal flora. When mucin is the only carbohydrate source, faecal flora exercised 
extensive mucinolytic activity to utilise this sole energy source for metabolism and 
growth purpose. But, when more ready-to-use carbohydrate (glucose) was present, an 
alternative and preferred metabolic pathway was used by some of the subpopulations, so 
that the production of mucinolytic enzymes were reduced to a lower level, and thus less 
mucinolytic activity was exhibited.  
In conclusion, the preliminary in vitro assays in this chapter have demonstrated that the 
potential probiotic strain L. reuteri DPC16 has no antagonistic effect on selected 
commensal probiotic bacteria, and does not degrade gastric mucin.  
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Chapter 6 
General discussions and conclusion 
This research investigated the antimicrobial activity of four different kinds of DPC16 
cell-free supernatants, namely MRSc FZMRSc MRSg and SGF. Paired with their 
pH-adjusted counterparts, these supernatants were tested in a series of in vitro 
antimicrobial assays against selected Gram-positive and Gram-negative pathogens. By 
determining their minimum effective dose, these supernatants were further studied for 
their effects on pathogen growth kinetics.  
A primary antimicrobial test showed that supernatants harvested from non-glycerol 
fermentation, MRSc and its freeze-dried derivative FZMRSc, had significant inhibitory 
effects against target pathogens, and these effects were mainly due to production of 
SCFA during incubation as evidenced by the negation of such activity from their 
pH-neutralized counterparts. In addition, this acidic effect was observed to reduce the 
pathogen growth rate and decrease the total pathogen cell numbers in a time course 
study.  
By using a two-step fermentation process with two-fold concentrated DPC16 resting 
cells, kinetic profiles of supernatants MRSg and SGF were obtained from 
glycerol-supplemented MRS broth and distilled water, respectively. The MRSg series 
has shown very strong antimicrobial activity against all target pathogens, nearly 
analogous to commercial antibiotics at its original dose. Moreover, this antimicrobial 
activity is pH-independent, and impacted on both Gram-negative and Gram-positive 
pathogens. It is assumed that reuterin may be present in MRSg. The kinetic profile of 
MRSg also showed that such antimicrobial activity was developed as a function of 
incubation time in a sigmoidal fashion reaching maximum inhibition by 6-8h of 
incubation and maintaining the same level thereafter. Using the determined minimum 
effective dose, a time course investigation provided further evidence of MRSg 
effectiveness on pathogen growth kinetic in elongating the lag phase, decreasing growth 
rate and lowering the total number of viable cells against all tested pathogens. Lastly, by 
comparing the antimicrobial activity of MRSg in high and low doses, it was found that 
MRSg, at a high dose, had a potent bactericidal effect resulting in pathogen cell death 
within 3h of treatment, while, at a low dose, MRSg was bacteriostatic by inducing a 
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stress response to pathogen cells during lag phase and hence delaying cell replication. 
However, this strong antimicrobial activity was also found to act on DPC16 itself by 
significantly reducing its cell viability. Nevertheless, this self-inhibiting activity 
occurred moderately and was tolerable until late in the fermentation.  
SGF, another glycerol fermentation product tested in this study, did not show a clear 
antimicrobial activity, did not develop a normal acidic cultural pH, and the cells 
producing SGF died very quickly. These suggest that there was no normal cell 
metabolism by the DPC16 cells in glycerol-water, and this strain may not be capable of 
producing reuterin without the presence of fermentable carbohydrate.  
The antimicrobial activity found in MRSg has matched with previously published 
characteristics of reuterin. Hence, a kinetic study on the production of reuterin by 
DPC16 resting cells was carried out. Initially, the growth kinetics of DPC16 was studied 
and it is found that the growth of this strain had a 8-10h lag phase, followed by a 4-6h 
exponential phase with a specific growth rate of 0.6 h-1 (or a doubling time of 1.16h), 
and resulted in a total number of viable cells of 4.23 x 109 CFU/mL (weighing 5.5 
g/L)and a pH drop from 6.50 to 4.44, after 20h of anaerobic incubation at 37°C in 
pre-reduced MRS broth.  
The reuterin production from glycerol bioconversion was analysed with both MRSg and 
SGF series. The results show that, in MRSg, 72.8% of used glycerol was converted to 
reuterin with a maximum production rate of 10.9 mM/h (or a maximum specific 
production rate of 73.7 mg/g CDW h-1) at 6h of secondary fermentation and a total 
amount of 62.5 mM of reuterin accumulated in the supernatant. However, there was no 
reuterin detected in SGF, even though glycerol has been absorbed by the concentrated 
resting cells. The huge difference in reuterin production between MRSg and SGF has 
suggested that this specific strain does not possess the capability to utilise glycerol in 
the absence of fermentable carbohydrate.  
Formation of reuterin in MRSg series followed a sigmoidal pattern of increase, which 
was similar to that of its antimicrobial activity; thus, a certain relationship was proposed 
between reuterin formation and the increased antimicrobial activity. Therefore, the 
major antimicrobial component in MRSg that accounted for its potent antimicrobial 
activity may be reuterin.  
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To assess the safety of this novel strain, an antagonistic assay against selected common 
probiotic bacteria was used to evaluate the same set of DPC16 supernatants in their 
effects on the growth of the target bacteria. This assay has shown that no DPC16 
supernatant had any significant inhibition effect on the growth of the tested probiotics. 
This has, one the other hand, proved that there was no bacteriocin synthesis in any 
DPC16 culture. However, there was no growth stimulatory effect detected in 
reuterin-containing MRSg supernatant, either. Next, as a second part of safety 
assessment, a mucin degradation assay was carried out by growing DPC16 together 
with its resting cells, controls and reference strains in a basal medium where purified 
porcine gastric mucin was incorporated as the only carbohydrate source. This classic 
mucin-degradation assay was conducted both in liquid and agarose media, and the 
results from both tests have shown that, as with the reference strain of B. lactis DR10, L. 
reuteri DPC16 does not have mucinolytic activity on gastric mucin, whereas the 
positive control of faecal flora cultures significantly degraded mucin for energy source 
due to their possession of responsible enzymes.  
Hence, L. reuteri DPC16 does not inhibit the growth of normal commensal microflora, 
and does not degrade epithelial gastric mucus, therefore it is safe to the GI environment 
of the host.  
Several significant findings have been reported in this thesis, especially the potent 
antimicrobial activity of reuterin-containing MRSg. This pH-independent bactericidal 
activity, exerted against both Gram-positive and Gram-negative pathogens, has great 
potential to be applied in food industry as preservative agent. Also, the host-safe 
character of MRSg has provided it with great advantage in pharmaceutical industry as a 
potential nature antibiotic reagent.  
However, there are still a few issues left unsolved. For example, reuterin in this research 
was detected as an equivalent of acrolein in supernatant solutions, but the reuterin was 
not purified. In future tests, a purification method introduced by Vollenweider et al. 
(2003) and the HPLC quantification by Chen et al. (2004) are recommended for reuterin 
analysis with higher accuracy and integrity. Another important kinetic parameter, 
utilisation of glucose in the reuterin production process, was not measured. This 
parameter can demonstrate critical information of cell metabolism during growth and 
the initiation of glycerol utilisation. Also, fermentation by-products, other than reuterin, 
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during the glycerol fermentation were not analysed in this thesis. To obtain a better 
understanding of the kinetics of glycerol fermentation by this DPC16 strain in MRS 
broth, a study on the above factors (e.g. HPLC quantification of pure reuterin, glucose 
and other end-products from glycerol fermentation in MRS broth) is essential and 
highly recommended for further investigations on this novel strain.  
This study has provided some evidence for the safety status of this novel strain of L. 
reuteri. However, to qualify for probiotic concept, there are a lot more safety 
assessments that need to be done. For example, it is worthwhile to investigate the full 
sequence the genomic DNA (especially on plasmids) of this strain for any existence of 
transmissible antibiotic-resistance gene, so that a further step can be made toward the 
GRAS category of the probiotics concept. 
The studies in this thesis only serve as a partial contribution towards the validation of 
the probiotic status claimed for this novel strain. The ultimate purpose was to gain 
knowledge and values from scientific discoveries, and then contribute to benefit human 
life.  
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Appendices  
Appendix 1  Ingredients of cultural growth media 
Table A.1  Composition of BHI (Brain Heart Infusion broth, BBL, BD; USA) 
Ingredients Amount 
(g per litre of distilled water) 
BHI solids 6.0 
Peptic digest of animal tissue 6.0 
Sodium chloride 5.0 
Glucose 3.0 
Pancreatic digest of gelatine 14.5 
Disodium phosphate 2.5 
Medium pH value: 7.2 ± 0.2 
 
Table A.2  Composition of MRS broth (Difco, Michigan; USA) 
Ingredients Amount (g per litre of distilled water) 
Protease peptone 10.0 
Beef extract 10.0 
Yeast extract 5.0 
Polysorbate 80 1.0 
Ammonium citrate 2.0 
Sodium acetate 5.0 
Dipotassium phosphate 2.0 
Magnesium sulphate 0.1 
Manganese sulphate 0.05 
Glucose 20.0 (equivalent to 110mM) 
Medium pH value: 6.5± 0.2 
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Appendix 2  Raw data and statistics  
Table A.3  A statistical analysis of antimicrobial activity of MRSc and FZMRSC against selected 
pathogens, compared to untreated controls. Percentage of inhibition on pathogen growth was 
calculated by comparing OD620 of treated pathogens with untreated controls, from triplicate 
readings with SEMs. Pathogen growth was significantly inhibited when symbol * P <0.05 or ** P 
<0.01 is presented. The P values are calculated from a paired sample T-test (n=3). 
 MRSc FZMRSc MRSc-pH FZMRSc-pH 
 %Inhibition 
 P 
value %Inhibition 
 P 
value %Inhibition 
 P 
value %Inhibition 
 P 
value 
S. Typhimurium  
 35.9% ± 
2.9% 0.009 
 42.7 % ± 
2.0% 0.002 
 3.9% ± 
2.6% 0.275 
 6.8 %± 
1.9% 0.061 
E. coli 
 35.9% ± 
0.7% 0.002 
 43.3 % ± 
3.5% 0.012 
 3.2% ± 
2.8% 0.361 
 6.3 %± 
3.9% 0.243 
S. aureus 
 18.0% ± 
0.6% 0.001 
 24.1 % ± 
3.1% 0.021 
 6.2% ± 
2.4% 0.111 
 4.4 %± 
4.8% 0.457 
L. 
monocytogenes 
 19.1% ± 
1.8% 0.018 
 23.9 % ± 
2.4% 0.013 
 5.5% ± 
3.3% 0.227 
 5.3 %± 
6.3% 0.484 
 
Table A.4  A statistical analysis comparing the antimicrobial activities between MRSc and 
FZMRSc (panel A), and between 8h-MRSg and its pH-adjusted counterpart (panel B). The P 
values were calculated from paired sample T-test (n=3), with P<0.05 indicating significance.  
A.  
Freeze-drying effect 
P-value S. Typhimurium E. coli O157:H7  S. aureus  L. monocytogenes 
MRSc versus FZMRSc 0.12 0.15 0.23 0.23 
B. 
pH adjustment effect 
P-value S. Typhimurium E. coli O157:H7  S. aureus  L. monocytogenes 
MRSg :pH-adjusted MRSg 0.31 0.27 0.18 0.53 
 
Table A.5  A statistical analysis of antimicrobial activity of original SGF series (non-pH-adjusted) 
against selected pathogens, comparing to non-treatment negative controls. The P values are 
calculated from a paired sample T-test (n=3), with P<0.05 indicating significance.  
 S. Typhimurium E. coli O157:H7 S. aureus L. monocytogenes 
SGF % Inhibition P-value % Inhibition P-value % Inhibition P-value % Inhibition P-value 
h1 6.9% ± 0.7% 0.089 4.1% ± 0.8% 0.135 9.5% ± 0.6% 0.064 3.9% ± 0.8% 0.174 
h2 13.2% ± 0.5% 0.007 6.4% ± 0.4% 0.089 17.3% ± 0.5% 0.002 6.4% ± 0.7% 0.076 
h3 9.8% ± 0.6% 0.031 5.6% ± 0.4% 0.099 12.6% ± 0.8% 0.019 5.3% ± 0.6% 0.088 
h4 10.3% ± 0.6% 0.045 5.6% ± 0.7% 0.176 12.5% ± 0.8% 0.030 5.3% ± 1.05% 0.229 
h5 8.8% ± 0.4% 0.056 5.7% ± 0.9% 0.086 10.1% ± 1.1% 0.059 5.9% ± 0.8% 0.124 
h6 8.5% ± 0.7% 0.067 4.9% ± 0.7% 0.082 9.6% ± 0.9% 0.062 3.5% ± 0.9% 0.322 
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h7 3.8% ± 0.4% 0.261 2.7% ± 0.5% 0.108 8.3% ± 1.0% 0.067 3.4% ± 0.9% 0.348 
h8 2.5% ± 0.6% 0.236 1.3% ± 0.4% 0.121 4.1% ± 0.6% 0.156 1.0 % ± 0.8% 0.763 
Table A.6  A statistical analysis on the dose response of DPC16 supernatants antimicrobial activity 
against selected pathogens. Data are P-values calculated from a paired sample T-test (n=3), by 
comparing the growth of the treated pathogens and that of the untreated controls, where P<0.05 
indicates significance effect (inhibition or stimulation).  
A. MRSc 
Dilution fold 10  20  40  80  160  320  640  1280  2560  5120  
S. Typhimurium  0.003  0.004  0.015  0.026  0.049  0.239  0.496  0.402  0.774  0.797  
E. coli 0.013  0.012  0.012  0.011  0.096  0.047  0.113  0.110  0.144  0.025  
S. aureus 0.013  0.067  0.078  0.286  0.854  0.965  0.564  0.447  1.000  0.755  
L. monocytogenes 0.010  0.011  0.085  0.037  0.100  0.519  0.826  0.900  0.792  0.980  
B. FZMRSc 
Dilution fold 10  20  40  80  160  320  640  1280  2560  5120  
S. Typhimurium  0.007  0.004  0.013  0.043  0.050  0.067  0.092  0.048  0.440  0.515  
E. coli 0.000  0.000  0.008  0.007  0.009  0.053  0.080  0.007  0.011  0.034  
S. aureus 0.000  0.009  0.058  0.113  0.057  0.553  0.408  0.913  0.883  0.486  
L. monocytogenes 0.001  0.006  0.022  0.067  0.371  0.501  0.887  0.595  0.370  0.220  
C. MRSg 
Dilution fold 10  20  40  80  160  320  640  1280  2560  5120  
S. Typhimurium  0.000  0.000  0.000  0.013  0.011  0.010  0.075  0.017  0.136  0.128  
E. coli 0.002  0.002  0.002  0.009  0.018  0.038  0.071  0.080  0.112  0.049  
S. aureus 0.000  0.000  0.000  0.000  0.001  0.003  0.029  0.101  0.453  0.729  
L. monocytogenes 0.001  0.001  0.004  0.024  0.012  0.000  0.015  0.053  0.014  0.028  
D. SGF 
Dilution fold 10  20  40  80  160  320  640  1280  2560  5120  
S. Typhimurium 0.057  0.793  0.789  0.377  0.649  0.521  0.255  0.145  0.116  0.034  
S. aureus 0.217  0.118  0.131  0.254  0.385  0.064  0.283  0.310  0.649  0.819  
 
Table A.7  A statistical analysis on the viability of DPC16 resting cells enumerated at designated 
time of the secondary fermentation producing either MRSg or SGF.  Panel A, cell concentration 
measured at each time point of the secondary fermentation is expressed as mean log CFU/mL with 
SEMs, calculated from plate counts of quadruplicate comparing with that in the original inoculum; 
panel B, a comparison of cell viability between freshly harvested DPC16 cells and the starved and 
freeze-dried DPC16 cells. P values are calculated from a paired sample T-test (n=3), and indicate 
significance in reduced cell viability if P <0.01 is presented.  
A.  
MRSg Log CFU/mL P-value SGF Log CFU/mL P-value 
6hr 10.35 ± 0.01 0.0006 1hr 8.36 ± 0.03 0.0001 
8hr 10.11 ± 0.03 0.003 2hr 7.27 ± 0.05 1.92 x10
-5
 
10hr 9.64 ± 0.01 0.0002 3hr 5.03 ± 0.01 6.23 x10
-7
 
20hr 4.56 ± 0.03 2.59x10
-6
 4hr 3.79 ± 0.02 1.16 x10
-6
 
B. 
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Freeze-drying effect 
Cells viability Freshly harvested  Starved and freeze-dried Reduction %  P-value 
Log CFU/mL 11.47 ± 0.02 10.91 ± 0.02 72.5 0.0005 
 
Table A.8  A statistic analysis of the effects of DPC16 cell-free supernatants on the growth of 
selected probiotic cultures. Data are P-values calculated from a paired sample T-test (n=3), by 
comparing the growth of the treated probiotics to that of the untreated controls, where P<0.05 
indicates significance effect (inhibition or stimulation).  
P values MRSc MRSc pH adjust FZMRSc 
FZMRSc 
pH adjust MRSg 
MRSg 
pH adjust SGF 
L. acidophilus 0.058 0.091 0.073 0.059 0.13 0.51 0.34 
L. plantarum 0.055 0.28 0.21 0.27 0.20 0.58 0.19 
P. acidilactic  0.66 0.19 0.13 0.56 0.59 0.66 0.42 
B. lactis DR10 0.069 0.39 0.11 0.101 0.056 0.053 0.098 
 
 
Table A.9  Growth of LAB cultures, faecal flora and the heat-killed faecal flora in a variety of 
media with and without PGM supplementation. Values are means of OD620 calculated from 
triplicate readings with SEMs. A statistic analysis compared the growth of LAB cultures and faecal 
flora with that in the heat killed faecal flora, and P values calculated from a paired sample T-test 
with P<0.05 indicating significance are also presented.  
Culture 1% Glucose 0.3% PGM+1% Glucose 0.3% PGM 
 OD620 OD620 OD620 P-value 
LR 0.72±0.02 0.77±0.01 0.05±0.01 0.064 
LRg 0.86±0.02 0.82±0.04 0.06±0.01 0.051 
BbL 0.44±0.03 0.45±0.02 0.03±0.04 0.194 
FF 0.61±0.03 0.55±0.03 0.34±0.04 0.004 
HFF -0.02 -0.01 -0.03  
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Appendix 3 Standard curves for colorimetric assays of glycerol and 
acrolein-equivalent reuterin 
Table A.10  Preparation of glycerol standard for colorimetric determination of glycerol in L. 
reuteri DPC16 supernatants, with glycerol stock (1.25 g/mL, MW 92 g/mol).  
Glycerol standard  
(mg/mL) 
0 2 4 6 8 10 12 14 16 18 20 
Glycerol standard (mM) 0.0 21.7 43.5 65.2 87.0 108.7 130.4 152.2 173.9 195.7 217.4 
Standard Solution (mL) 1 1 1 1 1 1 1 1 1 1 1 
20% NaOH (mL) 1 1 1 1 1 1 1 1 1 1 1 
95% Ethanol (mL) 6 6 6 6 6 6 6 6 6 6 6 
10% CuCl2 (mL) 0.6 
0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 
additional Ethanol (mL) 1.4 
1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 1.4 
Final Volume (mL) 10 10 10 10 10 10 10 10 10 10 10 
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Figure A.1  Standard curve of glycerol in molar concentration. Data points are mean OD635 from 
duplicate readings with SEMs represented as vertical bars. A linear regression line and a 
mathematics equation with a fitting coefficient R2 are also presented.  
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Table A.11  Preparation of acrolein standard for colorimetric determination of reuterin in L. 
reuteri DPC16 supernatants, with acrolein stock (0.839 g/mL, MW 56 g/mol). Acrolein stock was 
1:1000 diluted prior to the rest of preparation.   
Acrolein standard (μg/10mL) 0 20 40 60 80 100 120 
Acrolein (mmol/L) 0.0 0.04 0.07 0.11 0.14 0.18 0.21 
Acrolein standard (mL) 0.00 0.24 0.48 0.72 0.95 1.19 1.43 
95% Ethanol(mL) 2.00 1.76 1.52 1.28 1.05 0.81 0.57 
10mM Tryptophan(mL) 0.5 0.5 0.5 0.5 0.5 0.5 0.5 
additional 95% Ethanol (mL) 1.2 1.2 1.2 1.2 1.2 1.2 1.2 
37%, 12M HCl (mL) 6.3 6.3 6.3 6.3 6.3 6.3 6.3 
Final Volume (mL) 10 10 10 10 10 10 10 
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Figure A.2  Standard curve of acrolein in molar concentration. Data points are mean OD560 from 
duplicate readings with SEMs represented as vertical bars. A linear regression line and an 
mathematics equation with a fitting coefficient R2 are also presented.  
